

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

A Multicenter Prospective Observational Study Protocol for Radiation Exposure from Gastrointestinal Fluoroscopic Procedures (REX-GI study)

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033604
Article Type:	Protocol
Date Submitted by the Author:	13-Aug-2019
Complete List of Authors:	Nishida, Tsutomu ; Toyonaka Municipal Hospital, Department of Gastroenterology Hayashi, Shiro; Toyonaka Municipal Hospital, Department of Gastroenterology; Kento Hayashi Clinic, Department of Gastroenterology and Internal Medicine Takenaka, Mamoru ; Kindai University, Department of Gastroenterology Hosono, Makoto ; Kindai University, Department of Radiology Kogure, Hirofumi; The University of Tokyo, Department of Gastroenterology Hasatani, Kenkei ; Fukui Prefectural Hospital, Department of Gastroenterology Yamaguchi, Shinjiro ; Kansai Rosai Hospital, Department of Gastroenterology and Hepatology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Ihara, Hideyuki ; Tonan Hospital, Department of Gastroenterology Ihara, Hideyuki ; Tonan Hospital, Department of Gastroenterology Nagaike, Koji ; Suita Municipal Hospital, Department of Gastroenterology Nagaike, Koji ; Suita Municipal Hospital, Department of Gastroenterology and Hepatology, Yamada, Takuya ; Osaka Rosai Hospital, Department of Gastroenterology and Hepatology, Yakushijin, Takayuki ; Osaka General Medical Center, Department of Gastroenterology and Hepatology Takagi, Tadayuki ; Fukushima Medical University School of Medicine, Department of Gastroenterology Tsumura, Hidetaka ; Hyogo Cancer Center, Department of Gastroenterological Oncology, Kurita, Akira ; Kitano Hospital, Department of Gastroenterology and Hepatology, Digestive Disease Center Asai, Satoshi ; Tane General Hospital, Department of Gastroenterology Ito, Yukiko ; Japanese Red Cross Medical Center, Department of Gastroenterology Kuwai ; Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism

1 2 3		
3 4 5 7 8 9 10		
11 12 13 14		
15		
$\begin{array}{c} 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 21\\ 22\\ 32\\ 4\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 31\\ 32\\ 33\\ 45\\ 36\\ 37\\ 38\\ 9\\ 40\\ 41\\ 42\\ 43\\ 44\\ 56\\ 47\\ 48\end{array}$		
49 50 51 52		
53 54 55		
56 57 58		

	Maetani, Iruru ; Toho University Ohashi Medical Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine Ikezawa, Kenji ; Osaka International Cancer Institute, Department of Hepatobiliary and Pancreatic Oncology Iwashita, Takuji ; Gifu University Hospital, First Department of Internal Medicine Matsumoto, Kengo; Toyonaka Municipal Hospital, Department of Gastroenterology Inada, Masami ; Toyonaka Municipal Hospital, Department of Gastroenterology
Keywords:	Radiation Exposure, Diagnostic Reference Levels, ERCP, Gastrointestinal Fluoroscopic Procedure, Endoscopy < GASTROENTEROLOGY





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

1	A Multicenter Prospective Observational Study Protocol for Radiation Exposure
2	from Gastrointestinal Fluoroscopic Procedures (REX-GI study)
3	
4	Tsutomu Nishida ¹⁾ , Shiro Hayashi ¹⁾²⁾ , Mamoru Takenaka ³⁾ , Makoto Hosono ⁴⁾ , Hirofumi
5	Kogure ⁵⁾ , Kenkei Hasatani ⁶⁾ , Shinjiro Yamaguchi ⁷⁾ , Hirotsugu Maruyama ⁸⁾ , Hisashi
6	Doyama ⁹⁾ , Hideyuki Ihara ¹⁰⁾ , Toshiyuki Yoshio ¹¹⁾ , Koji Nagaike ¹²⁾ , Takuya Yamada ¹³⁾ ,
7	Takayuki Yakushijin ¹⁴⁾ , Tadayuki Takagi ¹⁵⁾ , Hidetaka Tsumura ¹⁶⁾ , Akira Kurita ¹⁷⁾ ,
8	Satoshi Asai ¹⁸⁾ , Yukiko Ito ¹⁹⁾ , Toshio Kuwai ²⁰⁾ , Yasuki Hori ²¹⁾ , Iruru Maetani ²²⁾ , Kenji
9	Ikezawa ²³⁾ , Takuji Iwashita ²⁴⁾ , Kengo Matsumoto ¹⁾ , Masami Inada ¹⁾
10	
11	1) Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka,
12	Japan
13	2) Department of Gastroenterology and Internal Medicine, Kento Hayashi Clinic,
14	Suita, Osaka, Japan
15	3) Department of Gastroenterology and Hepatology, Kindai University, Faculty of
16	Medicine, Osaka-Sayama, Osaka, Japan
17	4) Department of Radiology, Kindai University Faculty of Medicine, Osaka-Sayama,
18	Osaka, Japan
19	5) Department of Gastroenterology, Graduate School of Medicine, The University of
20	Tokyo, Tokyo, Japan
21	6) Department of Gastroenterology, Fukui Prefectural Hospital, Fukui, Fukui, Japan
22	7) Department of Gastroenterology and Hepatology, Kansai Rosai Hospital,

- -		
2		
3		
4		
5	00	
6	23	Amagasaki, Hyogo, Japan
7		
8	24	8) Department of Gastroenterology, Osaka City University, Graduate School of
9	21	of Department of Cabacemerology, Coaka only envelony, Cradade Concer of
10		
11	25	Medicine, Osaka, Osaka, Japan
12		
13	26	0) Department of Castroonterology, Johikawa Profestural Central Heapital, Kanazawa
14	20	9) Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa,
15		
16	27	Ishikawa, Japan
17		
18	00	10) Department of Ocetro enterplany. Tenen Lleanitel, Conners, Lleidveide, Janen
19	28	10) Department of Gastroenterology, Tonan Hospital, Sapporo, Hokkaido, Japan
20		
21	29	11) Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation
22		,
23	00	
24	30	for Cancer Research, Ariake, Tokyo, Japan
25		
26	31	12) Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka,
27		
28	20	
29	32	Japan
30		
31	33	13) Department of Gastroenterology and Hepatology, Osaka-Rosai Hospital,
32		
33	34	Sakai, Osaka, Japan
34	94	Saka, Sapan
35		
36	35	14) Department of Gastroenterology and Hepatology, Osaka General Medical Center,
37		
38	36	Osaka, Osaka, Japan
39 40	00	
40 41		
41	37	15) Department of Gastroenterology, Fukushima Medical University School of
42		
44	38	Medicine, Fukushima, Japan
45		
46	39	16) Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan
47		
48	40	
49	40	17) Department of Gastroenterology and Hepatology, Digestive Disease Center, Kitano
50		
51		
52	41	Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Osaka, Japan
53		
54		
55	42	18) Department of Gastroenterology, Tane General Hospital, Osaka, Osaka, Japan
56		
57	43	19) Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo,
58		, ,
59		
60		

	3
44	Japan
45	20) Department of Gastroenterology, National Hospital Organization, Kure Medical
46	Center and Chugoku Cancer Center, Kure, Japan
47	21) Department of Gastroenterology and Metabolism, Nagoya City University Graduate
48	School of Medical Sciences, Nagoya, Japan
49	22) Division of Gastroenterology and Hepatology, Department of Internal
50	Medicine, Toho University Ohashi Medical Center, Tokyo, Japan
51	23) Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer
52	Institute, Osaka, Osaka, Japan
53	24) First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan
54	
55	Address all correspondence to: Tsutomu Nishida, M.D.
56	Department of Gastroenterology, Toyonaka Municipal Hospital
57	4-14-1 Shibahara, Toyonaka, Osaka 560-8565 Japan
58	Email: tnishida.gastro@gmail.com
59	Tel: +81-6-6843-0101
60	
61	Email address: Tsutomu Nishida: tnishida. gastro@gmail.com, Shiro Hayashi:
62	hayashishiro1976@yahoo.co.jp, Mamoru Takenaka: mamoxyo45@gmail.com, Makoto
63	Hosono: hosono@med.kindai.ac.jp, Hirofumi Kogure: kogureh-tky@umin.ac.jp, Kenkei
64	Hasatani: hasatani9@yahoo.co.jp, Shinjiro Yamaguchi: smay-0608@diary.ocn.ne.jp,

3 4		
5 6 7	65	Hirotsugu Maruyama: <u>hiromaruyama99@gmail.com</u> , Hisashi Doyama:
8 9	66	<u>doyama.134@gmail.com</u> , Hideyuki Ihara: <u>h-ihara@tonan.gr.jp</u> , Toshiyuki Yoshio:
10 11 12	67	toshiyuki.yoshio@jfcr.or.jp, Koji Nagaike: nagaike.koji@gmail.com, Takuya Yamada:
13 14 15	68	yamtak1973@gmail.com, Takayuki Yakushijin: yakushijin@gh.opho.jp, Tadayuki
16 17	69	Takagi: <u>daccho@fmu.ac.jp</u> , Hidetaka Tsumura: <u>h.tsumura@hp.pref.hyogo.jp</u> , Akira
18 19 20	70	Kurita: kuritaaki1976@gmail.com, Satoshi Asai: bonyaritetsu1226@hotmail.co.jp,
21 22	71	Yukiko Ito: <u>yukikomd1224@gmail.com</u> , Toshio Kuwai: <u>toshiokuwai@gmail.com</u> ,
23 24 25	72	Yasuki Hori: yhori@med.to.jp , Iruru Maetani: mtnir50637@med.to.jp , Iruru Iru
26 27	73	<u>u.ac.jp</u> , Kenji Ikezawa: <u>ikezawa-ke@mc.pref.osaka.jp</u> , Takuji Iwashita:_
28 29 30	74	takuji@w7.dion.ne.jp, Kengo Matsumoto: ken5@gh.med.osaka-u.ac.jp, Masami Inada:
31 32	75	inada-intoyo@chp.toyonaka.osaka.jp
33 34 35	76	
36 37	77	inada-intoyo@chp.toyonaka.osaka.jp Word counts: 2276 words
38 39 40	78	
41 42	79	Keywords: Radiation Exposure, Diagnostic Reference Levels, ERCP, Gastrointestinal
43 44 45	80	Fluoroscopic Procedure, Endoscopy.
46 47	81	
48 49		
50		
51 52		
53		
54		
55		
56 57		
58		
59		
60		

BMJ Open

4		
5 6 7	82	ABSTRACT
8 9 10	83	INTRODUCTION: Recently, the use of various endoscopic procedures under X-ray
10 11 12	84	fluoroscopic guidance, such as endoscopic retrograde cholangiopancreatography
13 14 15	85	(ERCP), interventional endoscopic ultrasonography (EUS), enteral endoscopy, and
15 16 17	86	stenting, has been rapidly increasing because of the minimally invasive nature of these
18 19 20	87	procedures compared to that of surgical intervention. With the spread of computed
20 21 22	88	tomography and fluoroscopic interventions, including endoscopic procedures under X-
23 24 25	89	ray guidance, high levels of radiation exposure (RE) from medical imaging have led to
23 26 27	90	major concerns throughout society. However, information about RE related to these
28 29 30	91	image-guided procedures is scarce, and their reference levels have not been
31 32	92	established. The aim of this study is prospectively to collect the actual RE dose and to
33 34 35	93	help establish diagnostic reference levels (DRLs) in the field of gastroenterology in
35 36 37	94	Japan.
38 39 40	95	METHODS AND ANALYSIS: This study is a multicenter, prospective observational
40 41 42	96	study that aims to collect the actual RE from treatments and diagnostic procedures,
43 44 45	97	including ERCP, interventional EUS, balloon-assisted enteroscopy, and enteral metallic
43 46 47	98	stent and enteral tube placement. We will measure the total fluoroscopy time (FT, min),
48 49 50	99	the total dose-area product (DAP, Gycm ²) and air-kerma (AK, mGy) of those
50 51 52	100	procedures. Because we will be collecting the actual RE data and identifying the
53 54 55	101	affecting factors through a prospective, nationwide design, this study will help to set the
56 57	102	DRLs of ERCP, interventional EUS, balloon-assisted enteroscopy, and enteral metallic
58 59 60	103	stent and enteral tube placement.

 ETHICS AND DISSEMINATION: This trial (Radiation EXposure from GastroIntestinal fluoroscopic procedures: REX-GI study) was registered with the UMIN Clinical Trials <text> Registry at http://www.umin.ac.jp/ctr/ with number UMIN000036525 (registered 1 May 2019). Approval was obtained from each institutional review board. The requirement for informed consent will be waived via the opt-out method of each hospital website.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		7
2 3		
4 5		
6 7	110	Article summary
8 9 10	111	This is a research protocol of a study that aims to collect actual data on radiation
10 11 12	112	exposure (RE) and to identify the factors affecting RE during treatments and diagnostic
13 14 15	113	procedures under different types of fluoroscopic guidance for gastroenterology
16 17	114	procedures, including the gastrointestinal, hepatobiliary and pancreatic fields, to serve
18 19 20	115	as a basis for DRLs in Japan.
20 21 22	116	
23 24 25	117	Strengths and limitations of this study
25 26 27	118	• A large, multicenter, nationwide dataset of radiation exposure doses for
28 29	119	gastrointestinal fluoroscopic procedures, including endoscopic retrograde
30 31 32	120	cholangiopancreatography, interventional endoscopic ultrasonography, balloon-
33 34	121	assisted enteroscopy, and enteral metallic stent and enteral tube placement, serves
35 36 37	122	as a basis for the diagnostic reference levels in Japan.
38 39	123	• This study will include data from relatively recently launched fluoroscopic systems.
40 41 42	124	Therefore, these data may not always be valid for old models of fluoroscopic
43 44 45	125	systems.
46 47	126	This study will be conducted in hospitals where gastroenterologists or endoscopists
48 49 50	127	who are concerned about medical radiation exposure work. Therefore, the collected
51 52	128	values of radiation exposure may be lower than those in the real world.
53 54 55	129	
56 57		
58 59		
60		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

130 INTRODUCTION

131	Medical radiation is widely used in both medical imaging and radiation treatment. In
132	medical imaging, fluoroscopy employs radiation to show a continuous X-ray image on a
133	monitor and plays a major role in the daily practices of gastroenterology, digestive
134	endoscopy, and hepatobiliary and pancreatic studies. Radiological medical imaging
135	has both benefits and drawbacks for patients. The latter is split into two types:
136	deterministic risks ¹ , determined by the threshold dose, as represented by skin injury;
137	and stochastic risks, determined by a linear no-threshold model, such as cancer risk ² .
138	Therefore, all medical staff involved in medical radiation are required to have correct
139	knowledge of the appropriate use of medical radiation. Historically, medical radiation
140	has rapidly increased since the 1990s with the spread of computed tomography (CT),
141	and radiation-associated cancer risk was recognized in the same period, even with
142	small doses ^{3 4 5} . In particular, the use of CT has increased approximately 12-fold in the
143	United Kingdom and more than 20-fold in the United States in the last 25 years ⁶ .
144	The International Atomic Energy Agency (IAEA), the International Commission on
145	Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects
146	of Atomic Radiation (UNSCEAR), and other radiological societies have been trying to
147	manage medical RE according to the "as low as reasonably achievable" (ALARA)
148	principle by establishing diagnostic reference levels (DRLs) to optimize protection from
149	medical radiation. The concept of DRLs was first introduced by ICRP 73 7 in 1996.
150	Then, the ICRP emphasized the important role of DRLs as a tool for optimizing patient
151	protection ⁸⁹ . Accordingly, the ICRP set specific target levels for various X-ray-related

Page 11 of 37

BMJ Open

5		
6 7	152	procedures in 2007 ⁸ . This movement of setting DRLs has been led by radiation-related
8 9 10	153	societies in each region, although mainly in Western countries. The ICRP 135
11 12	154	recommends that all individuals who are involved in patient procedures with the risk of
13 14 15	155	medical exposure should be familiar with the DRL process as a tool for optimizing
16 17	156	protection ¹⁰ . DRLs are now widely accepted in not only Western countries but also
18 19 20	157	Japan (Japan DRLs 2015) 11 , and DRLs have been the global standard for all
20 21 22	158	procedures that use ionizing radiation. The introduction of DRLs in the UK could
23 24 25	159	achieve a reduction in radiation dose of approximately 50% in typical X-ray
25 26 27	160	examinations over 15 years ¹² . However, there is still not enough available data on RE
28 29 30	161	for gastrointestinal fluoroscopic procedures, such as endoscopic retrograde
31 32	162	cholangiopancreatography (ERCP), interventional endoscopic ultrasonography (EUS),
33 34 35	163	small bowel endoscopy, and enteral stent placement; these techniques are still being
36 37	164	developed and have recently been used with increasing frequency ¹³ .
38 39 40	165	Our gastroenterologists and endoscopists are still unfamiliar with the DRL concept.
40 41 42	166	Among gastrointestinal endoscopy associations, the 2012 European Gastrointestinal
43 44 45	167	Endoscopy Society (ESGE) guidelines for radiation protection states that the entrance
46 47	168	skin dose (ESD; approximately equivalent to air-kerma in this study) and kerma-area
48 49 50	169	product (KAP; approximately equivalent to dose-area product (DAP) in this study)
50 51 52	170	during ERCP are 55-347 mGy and 3-115/8-333 Gycm ² , respectively, although
53 54 55	171	information regarding DRLs of ERCP is limited because this statement is based on
56 57	172	approximately only 600 cases of ERCP, including 7 reports ¹⁴ . No guidelines on RE
58 59 60	173	from the American Society for Gastrointestinal Endoscopy (ASGE) exist, but the ASGE

174	recommends measuring and documenting fluoroscopy time (FT) and radiation dose in
175	all ERCP procedures as a quality indicator (level of evidence: 2C) ¹⁵ . Although no
176	guidelines for exposure have been developed at the Japan Gastroenterological
177	Endoscopy Society (JGES), a description of FT exists in the item about ERCP in the
178	Japan Endoscopy Database (JED) ¹⁶ , which is scheduled to be implemented as a
179	nationwide endoscopic survey in 2020. Therefore, we aim to collect the actual RE data
180	and identify the affecting factors in the REX-GI study and to establish data based on
181	the DRLs of ERCP, interventional EUS, balloon-assisted enteroscopy, and enteral
182	metallic stent and enteral tube placement.

and enteral tube placement.

1		11
2 3		
4 5		
6 7	183	METHODS AND ANALYSIS
8 9	184	Aims
10 11 12	185	The primary aim of this nationwide, prospective study is to collect actual data on RE
13 14	186	and identify the factors affecting RE during treatments and diagnostic procedures
15 16 17	187	under different types of fluoroscopic guidance for gastroenterology procedures,
18 19	188	including the gastrointestinal, hepatobiliary and pancreatic fields, to serve as a basis
20 21 22	189	for DRLs in Japan.
23 24	190	
25 26 27	191	Design
28 29	192	This is a multicenter, prospective observational cohort study of consecutive patients
30 31 32	193	who underwent the following 5 treatments and diagnostic procedures under
33 34 35	194	fluoroscopic guidance in the field of gastroenterology: 1) ERCP, 2) interventional EUS,
36 37	195	3) balloon-assisted enteroscopy, 4) enteral metallic stent placement; and 5) enteral
38 39	196	tube placement. We examined the procedure time (min), total FT (min), AK (mGy),
40 41 42	197	DAP (Gycm ²), total number of roentgenography, and radiation dose rate (RDR)
43 44 45	198	(mGy/min) during the procedures. The participating clinicians will manage patients
43 46 47	199	according to usual clinical practice, and the patients will undergo the above 5
48 49	200	procedures. For analysis, all data, including the related variables and outcome data
50 51 52	201	(Tables 1 and 2), will be collected for all patients. The study (Radiation EX posure from
53 54 55	202	GastroIntestinal fluoroscopic procedures: REX-GI study) was registered with the UMIN
55 56 57	203	Clinical Trials Registry at http://www.umin.ac.jp/ctr/ with number UMIN000036525
58 59 60	204	(registered 1 May 2019).

3 4		
5 6 7	205	
8 9	206	Setting
10 11 12	207	The study was conducted at 7 university hospitals, 4 cancer centers, 9 general
13 14 15	208	hospitals and 2 municipal hospitals in Japan. The participating hospitals are Toyonaka
16 17	209	Municipal Hospital, Kindai University, the University of Tokyo, Fukui Prefectural
18 19 20	210	Hospital, Kansai Rosai Hospital, Osaka City University, Ishikawa Prefectural Central
21 22	211	Hospital, Tonan Hospital, Japanese Foundation for Cancer Research, Suita Municipal
23 24 25	212	Hospital, Osaka Rosai Hospital, Osaka General Medical Center, Fukushima Medical
26 27	213	University School of Medicine, Hyogo Cancer Center, Kitano Hospital, Tane General
28 29 30	214	Hospital, Japanese Red Cross Medical Center, Kure Medical Center and Chugoku
31 32	215	Cancer Center, Nagoya City University Hospital, Toho University Ohashi Medical
33 34 35	216	Center, Osaka International Cancer Institute, and Gifu University Hospital (Figure 1).
36 37	217	The central sites of the study are located at the Toyonaka Municipal Hospital and
38 39 40	218	Kindai University.
41 42	219	
43 44 45	220	Study population
46 47	221	We will include all patients following usual clinical care who underwent the following
48 49 50	222	treatments and diagnostic procedures under fluoroscopic guidance: 1) ERCP; 2)
51 52	223	interventional EUS; 3) balloon-assisted enteroscopy; 4) enteral metallic stent
53 54 55	224	placement; and 5) enteral tube placement. There is no age restriction. We will exclude
56 57 58 59 60	225	patients who do not want to participate in this study via the <i>opt-out</i> method of each

2		
3		
4 5		
5 6	226	hospital website and patients who the attending physicians judge inadequate for this
7 8		
9	227	study.
10		
11 12	228	
13	000	
14 15	229	Primary outcomes
16	230	The primary outcomes will be the total FT (min), RDR (mGy/min), dose-area
17	200	
18 19	231	parameters (AK (mGy) and DAP (Gycm ²)) and total number of imaging studies that the
20		
21	232	patients who meet the individual inclusion and exclusion criteria will undergo (Table 1).
22 23		
24	233	
25		\sim
26 27	234	Secondary outcomes
28	005	
29	235	The secondary outcome will be the RE-related factors that affect the radiation dose in
30 31	236	each procedure. The details are shown in Table 2.
32	200	each procedure. The details are shown in Table 2.
33 34	237	
35		
36	238	Setting the sample size
37 38		
39	239	According to the preliminary questionnaire survey (data not shown), the numbers of
40		
41 42	240	examinations per year in the 8 centers that plan to participate in March 2019 are 4000
43		
44	241	ERCP procedures, 125 EUS procedures, 320 small intestine endoscopy procedures,
45 46	242	44 econheged start placements, 150 gestreductional start placements, 75 colorectal
47	242	44 esophageal stent placements, 150 gastroduodenal stent placements, 75 colorectal
48	243	stent placements, 180 transanal ileus tube placements, and 75 ileus tube placements.
49 50	210	
51	244	To set the DRL and to reduce intraprocedural variability in each hospital, we believe
52 53		
55 54	245	that initially enrolling a high number of facilities and patients is desirable; therefore, we
55		
56 57	246	did not set an upper limit for the goals.
57 58		
59	247	
60		

1		14
2 3		
4 5 6	248	Data analysis plan
7 8 9	249	Continuous variables will be expressed as medians with interquartile ranges. The
10 11 12	250	categorical variables will be expressed as numbers in each category or as frequencies.
13 14 15	251	Simple linear regression analysis will be performed to identify the relationships
16 17	252	between procedure time, FT and RD. A multiple linear regression analysis will be
18 19 20	253	performed to identify the factors related to RD. A P value of 0.05 will be considered
21 22	254	statistically significant. All statistical analyses will be performed with JMP software
23 24 25	255	(SAS Institute, Inc., Cary, NC, USA).
26 27	256	
28 29 30	257	Patient and public involvement and patient recruitment
31 32	258	Clinical factors related to ERCP and interventional EUS have been retrospectively
33 34 35	259	collected at two sites (Toyonaka Municipal Hospital and Kindai University) 17-20 . We
36 37 38	260	used those published data to develop plans for the design or implementation of the
39 40	261	study and to determine the research question or the outcome measures. No patients
41 42 43	262	were requested to advise us on the interpretation or writing up of results. There are no
43 44 45	263	plans to disseminate the results of the research to study participants, but we will
46 47 48	264	consider disseminating the results of the research to the relevant patient community.
49 50	265	
51 52 53	266	Data collection
54 55	267	The clinical factors have been modified to comply with local patient flow and
56 57 58	268	administrative requirements and have been assessed and approved by the study
59 60	269	steering committee. Case report forms will be de-identified after all data points have

BMJ Open

15

3 4		
5 6 7	270	been completed and all data queries have been addressed. Data collection will be
8 9 10	271	scheduled to be performed at 3-month intervals to prevent data loss. Data analysis will
11 12	272	take place at the central study site (Kindai University). This study does not require data
13 14 15	273	monitoring due to its nature as an observational study without interventions. Data will
16 17	274	be retained for either a minimum of 5 years after the end of the study or for 10 years
18 19 20	275	after publication, whichever is later.
21 22 23	276	
24 25	277	Time plan
26 27 28	278	May 2019 - December 2020: Patient recruitment.
29 30	279	2021: Data analysis and writing and submission of the main manuscript for publication.
31 32 33	280	
34 35	281	Ethics and dissemination
36 37 38	282	This observational study will be conducted in accordance with the Declaration of
39 40	283	Helsinki, and approval has been obtained from each institutional review board. The
41 42 43	284	requirement for informed consent will be waived via the opt-out method of each
44 45	285	hospital website.
46 47 48	286	
49 50 51 52	287	Author contributions
53 54	288	Nishida T, Hayashi S (Toyonaka Municipal Hospital), and Takenaka M (Kindai
55 56 57	289	University) designed this study. Hosono M (Kindai University) critically reviewed the
58 59 60	290	protocol. Nishida T, Hayashi S (Toyonaka Municipal Hospital), Takenaka M (Kindai

Page 18 of 37

BMJ Open

291	University), Kogure H (The University of Tokyo), Hasatani K (Fukui Prefectural
292	Hospital), Yamaguchi S (Kansai Rosai Hospital), Maruyama H (Osaka City University),
293	Doyama H (Ishikawa Prefectural Central Hospita), Ihara H, (Tonan Hospital) Yoshio T
294	(Cancer Institute Hospital, Japanese Foundation for Cancer Research), Nagaike K
295	(Suita Municipal Hospital), Yamada T (Osaka-Rosai Hospital), Yakushijin T (Osaka
296	General Medical Center), Takagi T (Fukushima Medical University School of Medicine),
297	Tsumura H (Hyogo Cancer Center), Kurita A (Kitano Hospital), Asai S (Tane General
298	Hospital), Ito Y (Japanese Red Cross Medical Center), Kuwai T (National Hospital
299	Organization, Kure Medical Center and Chugoku Cancer Center), Hori Y (Nagoya City
300	University Graduate School of Medical Sciences), Maetani I (Toho University Ohashi
301	Medical Center), Ikezawa K (Osaka International Cancer Institute), Iwashita T (Gifu
302	University Hospital), Matsumoto K, and Inada M (Toyonaka Municipal Hospital)
303	participated this study and will recruit the patients. All authors accepted the final
304	version of the protocol (ver. 1.1: 2019-Mar-14, ver.1.5: 2019-July-15).
305	
306	Acknowledgements and collaborators
307	We thank all the collaborators who cooperated in this first nationwide study of the
308	Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI).
309	The collaborators of the REX-GI study are Mitsuhiro Fujishiro (Nagoya University
310	Graduate School of Medicine), Masashi Yamamoto, Dai Nakamatsu, Kaori Mukai, Kei
311	Takahashi, Aya Sugimoto, Naoto Osugi, Yu Higaki, Ryo Tomita, Tatsuya Sakamoto,

BMJ Open

1		
2 3		
4		
5 6 7	312	Emi Meren, Kazuki Aochi, Shinji Kuriki, Li-sa Chang, and Koji Fukui (Toyonaka
8 9 10	313	Municipal Hospital), Yousuke Nakai (The University of Tokyo), Takahiro Suda
11 12	314	(Kansai Rosai Hospital), Kazuhiro Matsunaga (Ishikawa Prefectural Central
13 14 15	315	Hospital), Tetsuya Sumiyoshi (Tonan Hospital), Takashi Sasaki, Atsuko Tamashiro,
16 17	316	Hiroyuki Hatamori (Cancer Institute Hospital, Japanese Foundation for Cancer
18 19 20	317	Research), Takumi Kanagawa, Yuichi Yoshida, Masafumi Naito(Suita Municipal
21 22	318	Hospital), Shuji Ishii (Osaka General Medical Center), Takuto Hikichi (Fukushima
23 24 25	319	Medical University School of Medicine), Naoki Fujimoto (Tane General Hospital), Ikuya
26 27	320	Miki (Hyogo Cancer Center), Yuzuru Tamaru (National Hospital Organization Kure
28 29 30	321	Medical Center and Chugoku Cancer Center), Hiromi Kataoka, Kazuki Hayashi
31 32	322	(Nagoya City University Graduate School of Medical Sciences), Hiroaki Shigoka (Toho
33 34 35	323	University Ohashi Medical Center).
36 37	324	
38 39 40	325	Funding statement
41 42	326	This research received no specific grants from any funding agency in the public,
43 44 45	327	commercial or not-for-profit sectors.
46 47 48	328	
49 50 51	329	Publication and data sharing
52 53 54	330	After completion of the study, a main manuscript will be prepared to present the results
55 56	331	and will be submitted to a clinical journal for peer review. This study will ensure that the
57 58 59 60	332	public has access to the published data. A file containing the clean dataset used for

2 3		
4 5		
6 7	333	final analysis to determine the main data of the study, and an explanation of variables
8 9 10	334	will be made publicly accessible in an anonymized format.
11 12	335	
13 14 15	336	Consent for publication
16 17	337	The principal investigators will form a publication committee, which will include key
18 19 20	338	members of this study, and the committee will grant authorship according to individual
20 21 22	339	input. Investigators who do not qualify for authorship will be acknowledged by name in
23 24 25	340	the final manuscript.
26 27 28 29	341	
30 31 32 33 34	342	Conflicts of interest statement.
35 36 37 38	343	None of the authors have any competing interests arising from this research.
39 40 41 42 43 44		
45		
46 47		
48 49		
50 51		
52		
53 54		
55 56		
57		
58 59		
60		

BMJ Open

345	Discussion
346	Currently, the establishment of DRLs is an international requirement for protection from
347	medical radiation. Generally, for diagnostic radiology, national and regional DRLs are
348	usually set at the 75% percentile of the distribution of a typical sample dose ²¹ . All
349	physicians or medical staff who are involved in radiological imaging or procedures
350	under fluoroscopic guidance should be familiar with the DRL process as a tool for
351	optimizing protection. In addition, separate DRLs must be established for each country
352	and/or region because the equipment and procedure protocols can vary among
353	different regions ²¹ . However, the amount of RE depends on procedure complexity,
354	patient anatomy, lesion characteristics, disease severity ¹⁰ and type of fluoroscopic
355	devices ¹⁸ ; thus, setting the upper limit of radiation use by applying uniform standards is
356	difficult. Generally, DRLs are not dose limits and do not help distinguish between good
357	and poor medical practices ²¹ . Therefore, a high demand exists for a large amount of
358	real-world evidence. The 2015 Japan DRLs state that the methods for establishing
359	DRLs not only includes setting radiation dose levels but also includes determining the
360	dose quantities and units used to set the DRLs, thus standardizing the methodology for
361	dose measurements, data collection and identification of the applications of DRLs ¹¹ .
362	Unfortunately, most gastroenterologists are unfamiliar with not only DRLs but also
363	radiation protection because information on RE from gastrointestinal medical treatment
364	is currently very scarce, and few RE standards, including DRLs, have been established
365	worldwide. Given this background, the REX-GI study is planned as an observational,
366	nationwide study in Japan. Our results will help to promote radiation optimization and
	 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365

Page 22 of 37

patient radiation protection in gastroenterology studies, such as digestive endoscopy,

and hepatobiliary and pancreatic procedures.

<text>

Table 1. Primary outcomes

	BMJ Open	
Γable 1. Primary outcomes	BMJ Open BMJ Open 033604 on	2
Factors	Variables B	
Patients	Procedure type	
	Procedure type Age Age	
	• Sex	
Fluoroscopic system	Fluoroscopic device (company, device model, manufacturing ygar)	
	 Basic use setting: frame per second (FPS), radiation field (cm²/₂) 	
Radiation exposure		
	Air-Kerma (AK) (mGy)	
	Dose-area product (DAP) (Gycm ²)	
	Total number of roentgenography procedures	
	Radiation dose rate (RDR) (mGy/min)	
	 Total fluoroscopy time (FT) (min) Air-Kerma (AK) (mGy) Dose-area product (DAP) (Gycm²) Total number of roentgenography procedures Radiation dose rate (RDR) (mGy/min) 	
	yright.	

Table 2. Secondary outcomes

	BMJ Open 공
	en-20
Table 2. Secondar	BMJ Open no
Procedures	
ERCP	Radiation exposure-related factors Top (A) Surgically altered gastrointestinal anatomy Top
	Billroth I reconstruction, Billroth II reconstruction, Roux-en-Y reconstruction,
	pancreaticoduodenectomy
	(B) Type of endoscope
	(C) Naïve papilla
	(D) Indications for ERCP (including suspicion) are classified into the followin differences:
	1) Choledocholithiasis (maximum diameter, number of stones, presence of cholangitis, tube exchange
	for the above diseases, treatment for choledocholithiasis with or without galloon catheter, basket
	catheter, crusher, etc.)
	2) Distant malignant bile duct stricture (papillary tumor, distal cholangiocarcinoma, pancreatic cancer,
	etc.)
	3) Proximal malignant bile duct stricture (Hilar cholangiocarcinoma, intragepatic cholangiocarcinoma,
	gallbladder cancer, etc.)
	4) Pancreatic duct examination (pancreas cancer, intraductal papillary mecinous neoplasm, etc.)
	5) Other diseases apart from those listed above (benign bile duct stricture, pancreatobiliary junction
	abnormality, etc.)
	(E) Total procedure time (min) * Potential 1) Cannulation time Potential
	t by c
	by copyright

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

\sim	\sim
	-≺
_	0

mjope	BMJ Open			
n-2019				
mjopen-2019-03360				
	2) Treatment time			
scoppist: (LVE) †	(F) Experience of the high-volume endoscopist (HVE) or low-volume endosc			
brua	(G) Facility scale: The number of ERCP procedures per year			
y ⊠om	(H) Whether the fluoroscopic operator is inside or outside in the fluoroscopy			
ucoppancreatic stent, cytology,	(I) Various treatments (endoscopic sphincterotomy, stone treatment, bile duc			
first-use catheter, large balloon,	biopsy, naïve papilla, cannulation method, contrast agent, intubation time, fir			
oade	crusher, drainage area or method, stent type used, cholangioscopy)			
d fror	(J) Sedation: Medication and the depth of the anesthesia ‡			
G§)), choledochoduodenostomy	(A) Indication for interventional EUS (EUS-guided hepaticogastrostomy (HG	Interventional EUS		
ue (RV), pancreatic duct drainage	(CDS), cyst drainage (CD), antegrade treatment (AG), rendezvous technique			
njope	(PD)			
n. bm	(B) Total procedure time‡			
j.com	1) Endoscope insertion time			
on	2) Treatment time			
f	(C) Facility scale: The number of EUS interventions per year, the number of			
117, 2	aspiration (FNA) procedures per year			
2024 by gu	(D) Double stenting (presence or absence of duodenal stenosis)			
est. F	(F) Scope position			
rotec	(G) Sedation: Medication and the depth of anesthesia			
ted b	(A) Disease indicating balloon-assisted enteroscopy	Balloon-assisted		
v cop				
copyright				

	BMJ Open 2019-033604
	97-201 201
	2 9 9 9 0 3 2
enteroscopy	1) Hemostatic or bleeding confirmation
	2) Crohn's disease
	3) Small intestine tumor examination
	4) Others
	(B) Insertion site: perioral or transanal
	(C) Insertion length (cm)
	2) Cronn's disease February 2020 3) Small intestine tumor examination 4) Others 4) Others (B) Insertion site: perioral or transanal (C) Insertion length (cm) (C) Insertion length (cm) (D) Total procedure time (min) (C) Insertion length (cm)
Enteral metallic stent	
placement	 (A) Stent location 1) Esophagus (Upper/Mid-Low/Trans) 2) Gastro-duodenum (Above pylorus/Trans pylorus /Below pylorus) 3) Colon stent (Right/Left/Rectum) (B) Total procedure time (min) § 1) Endoscope insertion time 2) Treatment time
	2) Gastro-duodenum (Above pylorus/Trans pylorus /Below pylorus)
	3) Colon stent (Right/Left/Rectum)
	(B) Total procedure time (min) §
	1) Endoscope insertion time
	2) Treatment time
Enteral ileus tube	(A) Disease indicating ileus tube
placement	(B) Intranasal ileus tube insertion for ileal obstruction or transanal ileus tube \vec{i} sertion for malignant colonic
	obstruction 24
	1) Tube insertion length for peroral ileus tube placement (cm)
	2) The occlusion site for the transanal tube (Right/Left/Rectum)
	(D) Total procedure time (min) §
RCP: endoscopic retro	(D) Total procedure time (min) §
	pyrig

 omjopen-2019-03360

* Cannulation time is defined as the time from endoscope insertion until successful biliary cannulation and treatment time was defined as the time from successful biliary cannulation until the scope was removed from the patient. The total procedure time was defined as the time from endoscope insertion until the scope was removed from the patient. The total procedure time was defined as the time from endoscope insertion until the scope was removed from the patient. The total procedure time was defined as the time from endoscope insertion until the scope was removed from the patient (cannulation time + treatment time).
‡ Depth of anesthesia is divided into 3 levels based on the Richmond Agitation-Sedation Scale (RASS). Ramsay Scale, and Sedation-Agitation Scale (SAS): good, poor, and very bad. The good level is defined as RASS score: -5 ~ -1, SAS score: 1 ~ 3, and Ramsay score: 3 ~ 6 equivalent, without additional unplanned doses. The poor level is defined as RASS score: -1 ~ 3, and Ramsay score: 1 ~ 2, without physical restraint but with unplanned doses. The very bad level is defined as requiring physical restraint with a manpower considered dangerous, RASS score: +2 to +4, and SAS score: 6 to 7 regardless of Ramsay score.
† HVE: Endoscopists with more than 200 ERCP results and who have been involved in ERCP for over 10 years. LVE: Non-HVE endoscopists who perform ERCP.
‡ Endoscope insertion time is defined as the time from endoscope insertion until the initial EUS-guided needle puncture, and treatment time was defined as the time from initial EUS-guided needle puncture until the scope was removed from the patient. The total

procedure time was defined as the time from endoscope insertion until the scope was removed from the patient (endoscope insertion time +treatment time).

‡Endoscope insertion time is defined as the time from endoscope insertion until initial guidewire exploitation, and treatment time was defined as the time from initial guidewire exploration until the scope was removed from the patient. The defined as the time from endoscope insertion until the scope was removed from the patient (endoscope insertion time +treatment time).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Figure legends

Figure 1. The participating hospitals in this study.

<text>

References

- Henry MF, Maender JL, Shen Y, et al. Fluoroscopy-induced chronic radiation dermatitis: a report of three cases. *Dermatol Online J* 2009;15(1):3. [published Online First: 2009/03/14]
- 2. NCRP Commentary No. 27: Implications of Recent Epidemiologic Studies for the Linear-Nonthreshold Model and Radiation Protection 2018 [Available from: https://ncrponline.org/wp-

content/themes/ncrp/Pub_announcements/Commentary_No27_overview.pdf accessed July 9th, 2019.

- de González AB, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. *The Lancet* 2004;363(9406):345-51. doi: 10.1016/s0140-6736(04)15433-0
- 4. Jaffe D, Bowden GT. Ionizing radiation as an initiator: effects of proliferation and promotion time on tumor incidence in mice. *Cancer Res* 1987;47(24 Pt 1):6692-6.
- Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ* 2013;346:f2360. doi: 10.1136/bmj.f2360
- Khoramian D, Sistani S, Hejazi P. Establishment of diagnostic reference levels arising from common CT examinations in Semnan County, Iran. *Polish Journal of Medical Physics and Engineering* 2019;25(1):51-55. doi: 10.2478/pjmpe-2019-

- Radiological protection and safety in medicine. A report of the International Commission on Radiological Protection. *Ann ICRP* 1996;26(2):1-47. [published Online First: 1996/01/01]
- The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37(2-4):1-332. doi: 10.1016/j.icrp.2007.10.003 [published Online First: 2007/12/18]
- ICRP Publication 105. Radiation protection in medicine. Ann ICRP 2007;37(6):1-63.
 doi: 10.1016/j.icrp.2008.08.001 [published Online First: 2008/09/03]
- Vano E, Miller DL, Martin CJ, et al. ICRP Publication 135: Diagnostic Reference Levels in Medical Imaging. *Ann ICRP* 2017;46(1):1-144. doi: 10.1177/0146645317717209 [published Online First: 2017/10/27]
- 11. Dignostic Reference Levels Based on Latest Surveys in Japan -Japan DRLs 2015-
 - 2015[Availablefrom:http://www.radher.jp/J-RIME/report/DRLhoukokusyoEng.pdfaccessed July 9th, 2019.
- Hart D, Wall BF. UK population dose from medical X-ray examinations. *Eur J Radiol* 2004;50(3):285-91. doi: 10.1016/S0720-048X(03)00178-5 [published Online First: 2004/05/18]
- Hayashi S, Takenaka M, Hosono M, et al. Radiation exposure during image-guided endoscopic procedures: The next quality indicator for endoscopic retrograde cholangiopancreatography. *World Journal of Clinical Cases* 2018;6(16):1087-93. doi: 10.12998/wjcc.v6.i16.1087
- 14. Dumonceau JM, Garcia-Fernandez FJ, Verdun FR, et al. Radiation protection in


BMJ Open

digestive endoscopy: European Society of Digestive Endoscopy (ESGE)					
guideline. <i>Endoscopy</i> 2012;44(4):408-21. doi: 10.1055/s-0031-1291791					
[published Online First: 2012/03/23]					
15. Adler DG, Lieb JG, 2nd, Cohen J, et al. Quality indicators for ERCP. Gastrointestinal					
endoscopy 2015;81(1):54-66. doi: 10.1016/j.gie.2014.07.056 [published Online					
First: 2014/12/07]					
16. Matsuda K, Tanaka K, Fujishiro M, et al. Design paper: Japan Endoscopy Database					
(JED): A prospective, large database project related to gastroenterological					
endoscopy in Japan. Digestive endoscopy : official journal of the Japan					
Gastroenterological Endoscopy Society 2018;30(1):5-19. doi:					
10.1111/den.12964 [published Online First: 2017/09/15]					
17. Hayashi S, Nishida T, Shimakoshi H, et al. Mo2020 Novel Processing Engine for X-					
Ray Fluoroscopic Images (Faice-V Ns1) Can Reduce Radiation Exposure in the					
Procedure of ERCP But Keep the Quality of Images. Gastrointestinal endoscopy					
2017;85(5):AB518. doi: 10.1016/j.gie.2017.03.1207					
18. Hayashi S, Nishida T, Matsubara T, et al. Radiation exposure dose and influencing					
factors during endoscopic retrograde cholangiopancreatography. PloS one					
2018;13(11):e0207539. doi: 10.1371/journal.pone.0207539 [published Online					
First: 2018/11/20]					
19. Hayashi S, Higaki Y, Tomita R, et al. 940 Disease Site and Processing Engine Affect					
Radiation Exposure Dose during Ercp. Gastrointestinal endoscopy					

2018;87(6):AB137. doi: 10.1016/j.gie.2018.04.1348

- 20. Takenaka M, Hayashi S, Nishida T, et al. Mo1090 EXAMINATION OF ACTUAL RADIATION EXPOSURE DOSE OF THE PATIENTS WHO PERFORMED EUS-GUIDED DRAINAGE (EUS-BD/EUS-PD/EUS-CD). *Gastrointestinal endoscopy* 2019;89(6):AB444-AB45. doi: 10.1016/j.gie.2019.03.1247
- IC LOQ(1):W1-3. doi: 1 J 21. Vassileva J, Rehani M. Diagnostic reference levels. AJR American journal of roentgenology 2015;204(1):W1-3. doi: 10.2214/AJR.14.12794 [published Online First: 2014/12/30]

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

30				
31				Page
32 33			Reporting Item	Number
34 35 36 37	Administrative			
	information			
38 39 40	Title	<u>#1</u>	Descriptive title identifying the study design, population,	1
40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59			interventions, and, if applicable, trial acronym	
	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	6, 11
	Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	6, 11
	Protocol version	<u>#3</u>	Date and version identifier	16
	Funding	<u>#4</u>	Sources and types of financial, material, and other support	17
	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	15
	responsibilities: contributorship			
60	Fc	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3	Roles and responsibilities:	<u>#5b</u>	Name and contact information for the trial sponsor	N.A.
4 5 6 7	sponsor contact information			
, 9 10 11 12 13 14 15	Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N.A.
16 17 18 19 20 21 22 23	Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	12, 14
24 25 26	Introduction			
27 28 29 30 31	Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	8-10
32 33 34 35 36	Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	9
37 38 20	Objectives	<u>#7</u>	Specific objectives or hypotheses	9-10
39 40 41 42 43 44 45	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	11
46 47 49	Methods:			
48 49 50	Participants, interventions, and			
50 51 52	outcomes			
53 54 55 56 57 58	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	12
59 60		For peer rev	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	12
6 7 8 9	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	N.A.
10 11 12 13 14	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	N.A.
15 16 17 18 19	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	N.A.
20 21 22 23	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N.A.
24 25 26 27 28 29 30 31 32 33	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	13
34 35 36 37 38	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	15
39 40 41 42 43	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
44 45 46 47	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	14
48 49	Methods: Assignment			
50 51	of interventions (for			
52 53	controlled trials)			
55 54 55 56 57 58 59 60	Allocation: sequence generation	<u>#16a</u>	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	N.A.

Page 37 of 37			BMJ Open	
1 2 3			provided in a separate document that is unavailable to those who enrol participants or assign interventions	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	N.A.
	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	N.A.
	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N.A.
	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N.A.
25 26	Methods: Data			
27 28	collection, management, and			
29 30	analysis			
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 90 51 52 53 54 55 56 57 58 59 60	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14
	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	15
	Statistics: outcomes	<u>#20a</u> r peer rev	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	14

1 2 3	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N.A.
4 5 6 7 8 9	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non- adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	15
10 11	Methods: Monitoring			
12 13 14 15 16 17 18 19 20 21	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	15
22 23 24 25 26	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	15
27 28 29 30 31	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	N.A.
32 33 34 35 36 37	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N.A.
38 39	Ethics and			
40 41	dissemination			
42 43 44	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	15
45 46 47 48 49 50 51	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	N.A.
52 53 54 55 56 57 58 59	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	15
60	Fo	r peer rev	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5	Consent or assent: #26 ancillary studies		Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N.A.
6 7 8 9 10	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
11 12 13 14	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	17, 18
15 16 17 18 19	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17
20 21 22 23	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N.A.
53 54	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14
	Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	18
	Dissemination policy: reproducible research	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N.A.
	Appendices			
	Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and authorised surrogates	N.A.
	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N.A.
		st can b	stributed under the terms of the Creative Commons Attribution Licer e completed online using <u>https://www.goodreports.org/</u> , a tool made ation with <u>Penelope.ai</u>	
59	F -		view entry http://hypionen.hypionen.kypicena/cite/elegyt/avidelines/http:/	

BMJ Open

A Multicenter Prospective Observational Study Protocol for Radiation Exposure from Gastrointestinal Fluoroscopic Procedures (REX-GI study)

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-033604.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Nov-2019
Complete List of Authors:	Nishida, Tsutomu ; Toyonaka Municipal Hospital, Department of Gastroenterology Hayashi, Shiro; Toyonaka Municipal Hospital, Department of Gastroenterology; Kento Hayashi Clinic, Department of Gastroenterology and Internal Medicine Takenaka, Mamoru ; Kindai University, Department of Gastroenterology Hosono, Makoto ; Kindai University, Department of Radiology Kogure, Hirofumi; The University of Tokyo, Department of Gastroenterology Hasatani, Kenkei ; Fukui Prefectural Hospital, Department of Gastroenterology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Unara, Hideyuki ; Tonan Hospital, Department of Gastroenterology Ihara, Hideyuki ; Tonan Hospital, Department of Gastroenterology Nagaike, Koji ; Suita Municipal Hospital, Department of Gastroenterology Nagaike, Koji ; Suita Municipal Hospital, Department of Gastroenterology Yamada, Takuya ; Osaka Rosai Hospital, Department of Gastroenterology and Hepatology, Yakushijin, Takayuki ; Osaka General Medical Center, Department of Gastroenterology and Hepatology, Yakushijin, Takayuki ; Sushima Medical University School of Medicine, Department of Gastroenterology Tsumura, Hidetaka ; Hyogo Cancer Center, Department of Gastroenterologi al Oncology, Kurita, Akira ; Kitano Hospital, Department of Gastroenterology and Hepatology, Digestive Disease Center Asai, Satoshi ; Tane General Hospital, Department of Gastroenterology Ito, Yukiko ; Japanese Red Cross Medical Center, Department of Gastroenterology Kuwai ; Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism

	Maetani, Iruru ; Toho University Ohashi Medical Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine Ikezawa, Kenji ; Osaka International Cancer Institute, Department of Hepatobiliary and Pancreatic Oncology Iwashita, Takuji ; Gifu University Hospital, First Department of Interna Medicine Matsumoto, Kengo; Toyonaka Municipal Hospital, Department of Gastroenterology Inada, Masami ; Toyonaka Municipal Hospital, Department of Gastroenterology
Primary Subject Heading :	Gastroenterology and hepatology
Secondary Subject Heading:	Radiology and imaging, Public health, Research methods
Keywords:	Radiation Exposure, Diagnostic Reference Levels, ERCP, Gastrointestir Fluoroscopic Procedure, Endoscopy < GASTROENTEROLOGY

SCHOLARONE[™] Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2019-033604 on 26 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

RELEX ONL

1	A Multicenter Prospective Observational Study Protocol for Radiation Exposure
2	from Gastrointestinal Fluoroscopic Procedures (REX-GI study)
3	
4	Tsutomu Nishida ¹⁾ , Shiro Hayashi ¹⁾²⁾ , Mamoru Takenaka ³⁾ , Makoto Hosono ⁴⁾ , Hirofumi
5	Kogure ⁵⁾ , Kenkei Hasatani ⁶⁾ , Shinjiro Yamaguchi ⁷⁾ , Hirotsugu Maruyama ⁸⁾ , Hisashi
6	Doyama ⁹⁾ , Hideyuki Ihara ¹⁰⁾ , Toshiyuki Yoshio ¹¹⁾ , Koji Nagaike ¹²⁾ , Takuya Yamada ¹³⁾ ,
7	Takayuki Yakushijin ¹⁴⁾ , Tadayuki Takagi ¹⁵⁾ , Hidetaka Tsumura ¹⁶⁾ , Akira Kurita ¹⁷⁾ ,
8	Satoshi Asai ¹⁸⁾ , Yukiko Ito ¹⁹⁾ , Toshio Kuwai ²⁰⁾ , Yasuki Hori ²¹⁾ , Iruru Maetani ²²⁾ , Kenji
9	Ikezawa ²³⁾ , Takuji Iwashita ²⁴⁾ , Kengo Matsumoto ¹⁾ , Masami Inada ¹⁾
10	
11	1) Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka,
12	Japan
13	2) Department of Gastroenterology and Internal Medicine, Kento Hayashi Clinic,
14	Suita, Osaka, Japan
15	3) Department of Gastroenterology and Hepatology, Kindai University, Faculty of
16	Medicine, Osaka-Sayama, Osaka, Japan
17	4) Department of Radiology, Kindai University Faculty of Medicine, Osaka-Sayama,
18	Osaka, Japan
19	5) Department of Gastroenterology, Graduate School of Medicine, The University of
20	Tokyo, Tokyo, Japan
21	6) Department of Gastroenterology, Fukui Prefectural Hospital, Fukui, Fukui, Japan
22	7) Department of Gastroenterology and Hepatology, Kansai Rosai Hospital,

23	Amagasaki, Hyogo, Japan
24	8) Department of Gastroenterology, Osaka City University, Graduate School of
25	Medicine, Osaka, Osaka, Japan
26	9) Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa,
27	Ishikawa, Japan
28	10) Department of Gastroenterology, Tonan Hospital, Sapporo, Hokkaido, Japan
29	11) Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation
30	for Cancer Research, Ariake, Tokyo, Japan
31	12) Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka,
32	Japan
33	13) Department of Gastroenterology and Hepatology, Osaka-Rosai Hospital,
34	Sakai, Osaka, Japan
35	14) Department of Gastroenterology and Hepatology, Osaka General Medical Center,
36	Osaka, Osaka, Japan
37	15) Department of Gastroenterology, Fukushima Medical University School of
38	Medicine, Fukushima, Japan
39	16) Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan
40	17) Department of Gastroenterology and Hepatology, Digestive Disease Center, Kitano
41	Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Osaka, Japan
42	18) Department of Gastroenterology, Tane General Hospital, Osaka, Osaka, Japan
43	19) Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo,
40	Tay Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo,

2		
3 4		
5 6 7	44	Japan
8 9 10	45	20) Department of Gastroenterology, National Hospital Organization, Kure Medical
11 12	46	Center and Chugoku Cancer Center, Kure, Japan
13 14 15	47	21) Department of Gastroenterology and Metabolism, Nagoya City University Graduate
16 17	48	School of Medical Sciences, Nagoya, Japan
18 19 20	49	22) Division of Gastroenterology and Hepatology, Department of Internal
21 22	50	Medicine, Toho University Ohashi Medical Center, Tokyo, Japan
23 24 25	51	23) Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer
26 27	52	Institute, Osaka, Osaka, Japan
28 29 30	53	24) First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan
31 32	54	
33 34 35	55	Address all correspondence to: Tsutomu Nishida, M.D.
36 37	56	Department of Gastroenterology, Toyonaka Municipal Hospital
38 39 40 41	57	4-14-1 Shibahara, Toyonaka, Osaka 560-8565 Japan
42 43 44	58	Email: tnishida.gastro@gmail.com
45 46 47	59	Tel: +81-6-6843-0101
48 49 50	60	
51 52	61	Email addresses: Tsutomu Nishida: tnishida.gastro@gmail.com, Shiro Hayashi:
53 54 55	62	hayashishiro1976@yahoo.co.jp, Mamoru Takenaka: mamoxyo45@gmail.com, Makoto
56 57	63	Hosono: hosono@med.kindai.ac.jp, Hirofumi Kogure: kogureh-tky@umin.ac.jp, Kenkei
58 59 60	64	Hasatani: hasatani9@yahoo.co.jp, Shinjiro Yamaguchi: smay-0608@diary.ocn.ne.jp,

Page 6 of 43

BMJ Open

65	Hirotsugu Maruyama: <u>hiromaruyama99@gmail.com</u> , Hisashi Doyama:
66	doyama.134@gmail.com, Hideyuki Ihara: <u>h-ihara@tonan.gr.jp</u> , Toshiyuki Yoshio:
67	toshiyuki.yoshio@jfcr.or.jp, Koji Nagaike: nagaike.koji@gmail.com, Takuya Yamada:
68	yamtak1973@gmail.com, Takayuki Yakushijin: yakushijin@gh.opho.jp, Tadayuki
69	Takagi: <u>daccho@fmu.ac.jp</u> , Hidetaka Tsumura: <u>h.tsumura@hp.pref.hyogo.jp</u> , Akira
70	Kurita: kuritaaki1976@gmail.com, Satoshi Asai: bonyaritetsu1226@hotmail.co.jp,
71	Yukiko Ito: yukikomd1224@gmail.com, Toshio Kuwai: toshiokuwai@gmail.com,
72	Yasuki Hori: yhori@med.nagoya-cu.ac.jp , Iruru Maetani: mtnir50637@med.toho-
73	<u>u.ac.jp</u> , Kenji Ikezawa: <u>ikezawa-ke@mc.pref.osaka.jp</u> , Takuji Iwashita:_
74	takuji@w7.dion.ne.jp, Kengo Matsumoto: ken5@gh.med.osaka-u.ac.jp, Masami Inada:
75	inada-intoyo@chp.toyonaka.osaka.jp
76	
77	Word count: 2804 words
78	
79	Keywords: Radiation Exposure, Diagnostic Reference Levels, ERCP, Gastrointestinal
80	Fluoroscopic Procedure, Endoscopy.
81	

1		5
2 3 4		
5 6 7	82	ABSTRACT
8 9	83	INTRODUCTION: Recently, the use of various endoscopic procedures under X-ray
10 11 12	84	fluoroscopic guidance, such as endoscopic retrograde cholangiopancreatography
13 14	85	(ERCP), interventional endoscopic ultrasonography (EUS), enteral endoscopy, and
15 16 17	86	stenting, has been rapidly increasing because of the minimally invasive nature of these
18 19	87	procedures compared to that of surgical intervention. With the spread of computed
20 21 22	88	tomography and fluoroscopic interventions, including endoscopic procedures under X-
23 24 25	89	ray guidance, high levels of radiation exposure (RE) from medical imaging have led to
25 26 27	90	major concerns throughout society. However, information about RE related to these
28 29	91	image-guided procedures in gastrointestinal endoscopy is scarce, and the RE
30 31 32	92	reference levels have not been established. The aim of this study is to prospectively
33 34	93	collect the actual RE dose and to help establish diagnostic reference levels (DRLs) in
35 36 37	94	the field of gastroenterology in Japan.
38 39	95	METHODS AND ANALYSIS: This study is a multicenter, prospective observational
40 41 42	96	study that is being conducted to collect the actual RE from treatments and diagnostic
43 44 45	97	procedures, including ERCP, interventional EUS, balloon-assisted enteroscopy, enteral
46 47	98	metallic stent placement and enteral tube placement. We will measure the total
48 49 50	99	fluoroscopy time (FT, min), the total dose-area product (DAP, Gycm ²) and air-kerma
50 51 52	100	(AK, mGy) of those procedures. Because we are collecting the actual RE data and
53 54 55	101	identifying the influential factors through a prospective, nationwide design, this study
56 57	102	will provided guidance regarding the DRLs of ERCP, interventional EUS, balloon-
58 59 60	103	assisted enteroscopy, enteral metallic stent placement and enteral tube placement.

Page 8 of 43

-

104	ETHICS AND DISSEMINATION: This trial (Radiation EXposure from GastroIntestinal
105	fluoroscopic procedures: REX-GI study) was registered with the UMIN Clinical Trials
106	Registry at http://www.umin.ac.jp/ctr/ under number UMIN000036525 (registered 1
107	May 2019). Approval was obtained from the Institutional Review Board of Toyonaka
108	Municipal Hospital (2019-02-04). The need for informed consent will be waived via the
109	opt-out method of each hospital website.
110	
111	

7
1

1		7
2 3		
4		
5 6 7	112	Strengths and limitations of this study
8 9 10	113	• The large, multicenter, nationwide dataset of radiation exposure doses for
11 12	114	gastrointestinal fluoroscopic procedures in gastrointestinal endoscopy gathered in
13 14 15	115	this study will serve as a basis for the development of diagnostic reference levels in
16 17	116	Japan.
18 19 20	117	Gastrointestinal fluoroscopic procedures have been rapidly increasing in number
21 22 23	118	and complexity, but there are still not enough available local and national DRLs in
24 25	119	gastrointestinal endoscopy units.
26 27 28	120	These data may not be valid for old models of fluoroscopic systems because this
29 30	121	study will include data from fluoroscopic systems with available radiation data.
31 32 33	122	
34 35 36		
37 38		
39 40 41		
42 43 44		
45 46		
47 48		
49		
50 51		
52		
53 54		
55		
56 57		
58		
59 60		
00		

1 2 3		
4 5		
6 7	123	11
8 9 10	124	N
11 12	125	n
13 14 15	126	n
15 16 17	127	е
18 19	128	h
20 21 22	129	d
23 24	130	а
25 26 27	131	ri
28 29	132	ir
30 31 32	133	ra
33 34	134	с
35 36 37	135	n
38 39	136	to
40 41 42	137	р
43 44	138	h
45 46 47	139	tł
48 49	140	Т
50 51 52	141	F
53 54	142	0
55 56 57	143	а
58 59	144	re
60		

1

NTRODUCTION

 medical imaging, fluoroscopy employs radiation to show a continuous X-ray image on a monitor and plays a major role in the daily practices of gastroenterology, digestive endoscopy, and hepatobiliary and pancreatic studies. Radiological medical imaging has both benefits and drawbacks for patients. The latter is split into two types: deterministic risks ¹, determined by the threshold dose, as represented by skin injury, and stochastic risks, determined by a linear no-threshold model, such as the cancer risk ². There have been some reports on radiation-induced skin injury in cardiology and interventional radiology (IVR) ³, but reports from gastrointestinal endoscopy units are rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 & 6 & In particular, the use of CT} has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been attempting to manage medical radiation exposure (RE) according to the "as low as 	124	Medical radiation is widely used in both medical imaging and radiation treatment. In
 endoscopy, and hepatobiliary and pancreatic studies. Radiological medical imaging has both benefits and drawbacks for patients. The latter is split into two types: deterministic risks ¹, determined by the threshold dose, as represented by skin injury, and stochastic risks, determined by a linear no-threshold model, such as the cancer risk ². There have been some reports on radiation-induced skin injury in cardiology and interventional radiology (IVR) ³, but reports from gastrointestinal endoscopy units are rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	125	medical imaging, fluoroscopy employs radiation to show a continuous X-ray image on a
 has both benefits and drawbacks for patients. The latter is split into two types: deterministic risks ¹, determined by the threshold dose, as represented by skin injury, and stochastic risks, determined by a linear no-threshold model, such as the cancer risk ². There have been some reports on radiation-induced skin injury in cardiology and interventional radiology (IVR) ³, but reports from gastrointestinal endoscopy units are rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	126	monitor and plays a major role in the daily practices of gastroenterology, digestive
 deterministic risks ¹, determined by the threshold dose, as represented by skin injury, and stochastic risks, determined by a linear no-threshold model, such as the cancer risk ². There have been some reports on radiation-induced skin injury in cardiology and interventional radiology (IVR) ³, but reports from gastrointestinal endoscopy units are rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	127	endoscopy, and hepatobiliary and pancreatic studies. Radiological medical imaging
 and stochastic risks, determined by a linear no-threshold model, such as the cancer risk ². There have been some reports on radiation-induced skin injury in cardiology and interventional radiology (IVR) ³, but reports from gastrointestinal endoscopy units are rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	128	has both benefits and drawbacks for patients. The latter is split into two types:
 risk ². There have been some reports on radiation-induced skin injury in cardiology and interventional radiology (IVR) ³, but reports from gastrointestinal endoscopy units are rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	129	deterministic risks ¹ , determined by the threshold dose, as represented by skin injury,
 interventional radiology (IVR) ³, but reports from gastrointestinal endoscopy units are rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	130	and stochastic risks, determined by a linear no-threshold model, such as the cancer
 rare. However, all medical staff in gastrointestinal endoscopy units need to have correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	131	risk ² . There have been some reports on radiation-induced skin injury in cardiology and
 correct knowledge of the appropriate use of medical radiation. Historically, the use of medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	132	interventional radiology (IVR) ³ , but reports from gastrointestinal endoscopy units are
 medical radiation has rapidly increased since the 1990s with the spread of computed tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years 7. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	133	rare. However, all medical staff in gastrointestinal endoscopy units need to have
 tomography (CT), and the radiation-associated cancer risk was recognized in the same period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	134	correct knowledge of the appropriate use of medical radiation. Historically, the use of
 period, even when the doses of radiation were small ^{4 5 6}. In particular, the use of CT has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	135	medical radiation has rapidly increased since the 1990s with the spread of computed
 has increased approximately 12-fold in the United Kingdom and more than 20-fold in the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	136	tomography (CT), and the radiation-associated cancer risk was recognized in the same
 the United States in the last 25 years ⁷. The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	137	period, even when the doses of radiation were small $^{4\ 5\ 6}$. In particular, the use of CT
 The International Atomic Energy Agency (IAEA), the International Commission on Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), and other radiological societies have been 	138	has increased approximately 12-fold in the United Kingdom and more than 20-fold in
 141 Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects 142 of Atomic Radiation (UNSCEAR), and other radiological societies have been 	139	the United States in the last 25 years ⁷ .
142 of Atomic Radiation (UNSCEAR), and other radiological societies have been	140	The International Atomic Energy Agency (IAEA), the International Commission on
	141	Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects
143 attempting to manage medical radiation exposure (RE) according to the "as low as	142	of Atomic Radiation (UNSCEAR), and other radiological societies have been
	143	attempting to manage medical radiation exposure (RE) according to the "as low as

reasonably achievable" (ALARA) principle by establishing diagnostic reference levels

Page 11 of 43

BMJ Open

1 2 3 4 5 6 7 8 9 10 11 2 13 14 15 16 7 18 19 20 12 22 3 24 5 26 27 28 9 30 13 22 33 34 35 36 7 38 9 40 14 24 34 45 46 47 48 9 50 15 52	
47 48 49 50 51	

145	(DRLs) to optimize protection from medical radiation. The concept of DRLs was first
146	introduced by the ICRP 73 ⁸ in 1996. Then, the ICRP emphasized the important role of
147	DRLs as a tool for optimizing patient protection ^{9 10} . Accordingly, the ICRP set specific
148	target levels for various X-ray-related procedures in 2007 9. This movement of setting
149	DRLs has been led by radiation-related societies in each region, although the
150	movement has mainly been driven by Western countries. The ICRP 135 recommends
151	that all individuals who are involved in patient procedures with the risk of medical
152	exposure should be familiar with the DRL process as a tool for optimizing protection ¹¹ .
153	DRLs are now widely accepted in not only Western countries but also Japan (Japan
154	DRLs 2015) ¹² , and DRLs have become the global standard for all procedures that use
155	ionizing radiation. Legislation has made it mandatory to establish and record DRLs in
156	Europe, but that is not the case worldwide. The introduction of DRLs in the UK
157	achieved a reduction of approximately 50% in the radiation dose in typical X-ray
158	examinations over 15 years ¹³ . However, there is still not enough available data on RE
159	for gastrointestinal fluoroscopic procedures, such as endoscopic retrograde
160	cholangiopancreatography (ERCP), interventional endoscopic ultrasonography (EUS),
161	small bowel endoscopy, and enteral stent placement; these techniques are still being
162	developed and have recently been used with increasing frequency ¹⁴⁻¹⁶ .
163	Our gastroenterologists and endoscopists are still unfamiliar with the DRL concept.
164	Among the guidelines developed by gastrointestinal endoscopy associations, the 2012
165	European Gastrointestinal Endoscopy Society (ESGE) guidelines for radiation

Page 12 of 43

BMJ Open

166	protection state that the entrance skin dose (ESD; approximately equivalent to air-
167	kerma in this study) and kerma-area product (KAP; approximately equivalent to the
168	dose-area product (DAP) in this study) during diagnostic and therapeutic ERCP are 55-
169	347 mGy and 3-115/8-333 Gycm ² , respectively, although information regarding the
170	DRLs of ERCP is limited because this statement is based on only approximately 600
171	cases of ERCP in 7 reports ¹⁴ . No guidelines on RE from the American Society for
172	Gastrointestinal Endoscopy (ASGE) exist, but the ASGE recommends measuring and
173	documenting fluoroscopy time (FT) and radiation dose in all ERCP procedures as a
174	quality indicator (level of evidence: 2C) ¹⁷ . Although no guidelines for exposure have
175	been developed by the Japan Gastroenterological Endoscopy Society (JGES), a
176	description of FT exists in the item regarding ERCP in the Japan Endoscopy Database
177	(JED) ¹⁸ , which is scheduled to be implemented as a nationwide endoscopic survey in
178	2020.
179	Recently, various endoscopic procedures performed under fluoroscopic guidance are
180	rapidly increasing in popularity in gastrointestinal endoscopy units, where the aim is not
181	only diagnosis but also therapeutic intervention. The ICRP recommends that DRLs
182	should be used to manage patient doses during both diagnostic and interventional
183	procedures. There is difficulty in applying the DRL concept to interventional procedures
184	because the RE level depends on the complexity of the procedure and the individual
185	clinical circumstances ^{10 19 20} . There have been attempts to establish DRLs for IVR

procedures, where grouping by disease site may help minimize the wide distribution of
 RE ^{21 22}.

The Japanese DRLs were established on a basis of a survey and released in 2015; these guidelines defined the DRL value for fluoroscopically guided interventional procedures as a fluoroscopic radiation dose rate (interventional reference point dose rate) of 20 mGy/min¹². However, it did not include information for specific procedures in the field of gastroenterology ¹². Therefore, we aim to prospectively collect actual RE data and identify the influential factors, such as disease site, in this REX-GI study and to establish DRLs for the following interventional procedures in gastrointestinal endoscopy units: ERCP, interventional EUS, balloon-assisted enteroscopy, enteral metallic stent placement and enteral tube placement.

197	METHODS AND ANALYSIS
198	Aims
199	The primary aim of this nationwide, prospective study is to collect actual data on RE
200	and identify the factors affecting RE during treatments and diagnostic procedures
201	under different types of fluoroscopic guidance for gastroenterology procedures,
202	including the gastrointestinal, hepatobiliary and pancreatic fields, to serve as a basis
203	for the establishment of DRLs in Japan.
204	
205	Design
206	This is a multicenter, prospective observational cohort study of consecutive patients
207	undergoing the following 5 treatments and diagnostic procedures under fluoroscopic
208	guidance in the field of gastroenterology: 1) ERCP, 2) interventional EUS, 3) balloon-
209	assisted enteroscopy, 4) enteral metallic stent placement; and 5) enteral tube
210	placement. We will examine the procedure time (min), total FT (min), AK (mGy), DAF
211	(Gycm ²), total number of roentgenography procedures, and radiation dose rate (RDR
212	(mGy/min) during the procedures. The participating clinicians will manage patients
213	according to the usual clinical practice, and the patients will undergo the above 5
214	procedures. For the analysis, all data, including the related variables and outcome da
215	(Tables 1 and 2), will be collected for all patients. The study (Radiation EXposure from
216	GastroIntestinal fluoroscopic procedures: REX-GI study) was registered with the UM
217	Clinical Trials Registry at http://www.umin.ac.jp/ctr/ under the number UMIN0000365
218	(registered 1 May 2019).

3 4		
5 6 7	219	
8 9	220	Setting
10 11 12	221	The study will be conducted at 7 university hospitals, 4 cancer centers, 9 general
13 14	222	hospitals and 2 municipal hospitals in Japan. The participating hospitals are Toyonaka
15 16 17	223	Municipal Hospital, Kindai University, the University of Tokyo, Fukui Prefectural
18 19	224	Hospital, Kansai Rosai Hospital, Osaka City University, Ishikawa Prefectural Central
20 21 22	225	Hospital, Tonan Hospital, Japanese Foundation for Cancer Research, Suita Municipal
23 24	226	Hospital, Osaka Rosai Hospital, Osaka General Medical Center, Fukushima Medical
25 26 27	227	University School of Medicine, Hyogo Cancer Center, Kitano Hospital, Tane General
28 29	228	Hospital, Japanese Red Cross Medical Center, Kure Medical Center and Chugoku
30 31 32	229	Cancer Center, Nagoya City University Hospital, Toho University Ohashi Medical
33 34	230	Center, Osaka International Cancer Institute, and Gifu University Hospital (Figure 1).
35 36 37	231	Table 1 shows the fluoroscopic systems and units performing procedures under
38 39	232	fluoroscopic guidance in each institution. The central sites of the study are located at
40 41 42	233	the Toyonaka Municipal Hospital and Kindai University. The participating physicians
43 44	234	are gastroenterologists or endoscopists, including all experts and trainees working at
45 46 47	235	all involved hospitals. The quality of the fluoroscopic devices will be regularly monitored
48 49	236	according to the procedures in each institution.
50 51 52	237	
53 54	238	Study population
55 56 57	239	We will include all patients receiving usual clinical care who undergo the following
58 59	240	treatments and diagnostic procedures under fluoroscopic guidance: 1) ERCP; 2)

3 4		
5		
6 7	241	interventional EUS; 3) balloon-assisted enteroscopy; 4) enteral metallic stent
8 9 10	242	placement; and 5) enteral tube placement. There is no age restriction. We will exclude
10 11 12	243	patients who do not want to participate in this study via the opt-out method on each
13 14 15	244	hospital website and patients who the attending physicians judge to be unsuitable for
16 17	245	inclusion in this study.
18 19 20	246	
20 21 22	247	Primary outcomes
23 24 25	248	The primary outcomes will be the total FT (min), RDR (mGy/min), dose-area
26 27	249	parameters (AK (mGy) and DAP (Gycm ²) and the total number of imaging studies that
28 29 30	250	the patients who meet the individual inclusion and exclusion criteria will undergo (Table
31 32	251	2).
33 34 35	252	
36 37	253	Secondary outcome
38 39 40	254	The secondary outcome will be the RE-related factors that affect the radiation dose in
40 41 42	255	each procedure. The details are shown in Table 3.
43 44 45	256	
46 47	257	Setting the sample size
48 49 50	258	According to the preliminary questionnaire survey (data not shown), the numbers of
51 52	259	examinations per year in the 8 centers that plan to participate in March 2019 are as
53 54 55	260	follows: 4000 ERCP procedures, 125 EUS procedures, 320 small intestine endoscopy
56 57	261	procedures, 44 esophageal stent placements, 150 gastroduodenal stent placements,
58 59 60	262	75 colorectal stent placements, 180 transanal ileus tube placements, and 75 ileus tube

BMJ Open

2 3		
4 5		
6 7	263	placements. The ICRP 135 recommends using data from 20-30 facilities to set national
8 9 10 11 12	264	DRLs, and a survey for a particular examination in a facility should usually involve the
	265	collection of data from at least 20 patients ¹¹ .
13 14	266	To set the DRLs and to reduce intraprocedural variability in each hospital, we set the
15 16 17	267	minimum sample size to at least 400 patients for each procedure. We believe that
18 19 20	268	initially enrolling a high number of facilities and patients is desirable; therefore, we did
20 21 22	269	not set an upper limit for the goals.
23 24	270	
25 26 27	271	Data analysis plan
28 29 30	272	After obtaining the data, we will perform normality tests. Continuous variables will be
30 31 32	273	expressed as medians with interquartile ranges or means with standard deviations.
33 34	274	The categorical variables will be expressed as numbers in each category or as
35 36 37	275	frequencies. To explore surrogate markers of RD, simple linear regression analysis will
38 39 40	276	be performed to identify the relationships between procedure time, FT and RD. A
40 41 42	277	multiple linear regression analysis will be performed to identify the factors related to
43 44 45	278	RD. A P value of 0.05 will be considered statistically significant. All statistical analyses
46 47	279	will be performed with JMP software (SAS Institute, Inc., Cary, NC, USA).
48 49 50	280	
50 51 52	281	Patient and public involvement
53 54	282	Clinical factors related to ERCP and interventional EUS have been retrospectively
55 56 57	283	collected at two sites (Toyonaka Municipal Hospital and Kindai University) $^{\rm 2123-25}$. We
58 59 60	284	used those published data to develop plans for the design or implementation of the

2 3 4		
5 6 7	285	study and to determine the research question or the outcome measures. No patients
8 9 10	286	were asked to advise us on the interpretation or writing up of results. There are no
11 12	287	plans to disseminate the results of the research to study participants, but we will
13 14 15	288	consider disseminating the results of the research to the relevant patient community.
16 17	289	
18 19 20	290	Data collection
21 22	291	The clinical factors have been modified to comply with local patient flow and
23 24 25	292	administrative requirements and have been assessed and approved by the study
26 27	293	steering committee. We are collecting the password-protected case report forms by e-
28 29 30	294	mail from each institution; these will be de-identified after all data have been collected,
31 32	295	and all data queries have been addressed. A unique study identification number will
33 34 35	296	identify each participant and the associated clinical data. Data collection will be
36 37	297	performed at 3-month intervals to prevent data loss. Data analysis will take place at the
38 39 40	298	central study site (Kindai University). This study does not require data monitoring due
41 42	299	to its nature as an observational study without interventions. Data will be retained for
43 44 45	300	either a minimum of 5 years after the end of the study or for 10 years after publication,
46 47 48	301	whichever is later.
49 50 51	302	
52 53	303	Patient recruitment and time plan
54 55 56	304	Patient recruitment will be carried out at the participating hospitals from May 2019 -
57 58 59 60	305	December 2020.

4		
5 6 7	306	2021: Data analysis and writing and submission of the main manuscript for publication.
8 9 10	307	
10 11 12	308	Ethics and dissemination
13 14 15	309	This observational study will be conducted in accordance with the principles of the
16 17	310	Declaration of Helsinki, and approval has been obtained from the Institutional Review
18 19 20	311	Board of Toyonaka Municipal Hospital (2019-02-04) and the institutional review board
21 22	312	of each participating facility. The need for informed consent will be waived via the opt-
23 24 25	313	out method on each hospital website. The results of this study will be presented at
26 27	314	gastroenterology-, endoscopy-, or radiology-related congresses and will be published
28 29 30	315	in a peer-reviewed journal.
31 32	316	
33 34 35	317	
36 37 38	318	Author contributions
39 40 41	319	Nishida T, Hayashi S (Toyonaka Municipal Hospital), and Takenaka M (Kindai
42 43	320	University) designed this study. Hosono M (Kindai University) critically reviewed the
44 45 46	321	protocol. Nishida T, Hayashi S (Toyonaka Municipal Hospital), Takenaka M (Kindai
47 48	322	University), Kogure H (The University of Tokyo), Hasatani K (Fukui Prefectural
49 50 51	323	Hospital), Yamaguchi S (Kansai Rosai Hospital), Maruyama H (Osaka City University),
52 53	324	Doyama H (Ishikawa Prefectural Central Hospita), Ihara H, (Tonan Hospital) Yoshio T
54 55 56	325	(Cancer Institute Hospital, Japanese Foundation for Cancer Research), Nagaike K
57 58 59 60	326	(Suita Municipal Hospital), Yamada T (Osaka-Rosai Hospital), Yakushijin T (Osaka

•

327	General Medical Center), Takagi T (Fukushima Medical University School of Medicine),
328	Tsumura H (Hyogo Cancer Center), Kurita A (Kitano Hospital), Asai S (Tane General
329	Hospital), Ito Y (Japanese Red Cross Medical Center), Kuwai T (National Hospital
330	Organization, Kure Medical Center and Chugoku Cancer Center), Hori Y (Nagoya City
331	University Graduate School of Medical Sciences), Maetani I (Toho University Ohashi
332	Medical Center), Ikezawa K (Osaka International Cancer Institute), Iwashita T (Gifu
333	University Hospital), Matsumoto K, and Inada M (Toyonaka Municipal Hospital)
334	participated this study and will recruit the patients. All authors accepted the final
335	version of the protocol (ver. 1.1: 2019-Mar-14, ver.1.5: 2019-July-15).
336	
337	Acknowledgements and collaborators
338	We thank all the collaborators who are cooperating in this first nationwide study of the
338	We thank all the collaborators who are cooperating in this first nationwide study of the
338 339	We thank all the collaborators who are cooperating in this first nationwide study of the Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI).
338 339 340	We thank all the collaborators who are cooperating in this first nationwide study of the Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI). The collaborators involved in the REX-GI study are as follows: Mitsuhiro Fujishiro
338 339 340 341	We thank all the collaborators who are cooperating in this first nationwide study of the Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI). The collaborators involved in the REX-GI study are as follows: Mitsuhiro Fujishiro (Nagoya University Graduate School of Medicine), Masashi Yamamoto, Dai
338 339 340 341 342	We thank all the collaborators who are cooperating in this first nationwide study of the Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI). The collaborators involved in the REX-GI study are as follows: Mitsuhiro Fujishiro (Nagoya University Graduate School of Medicine), Masashi Yamamoto, Dai Nakamatsu, Kaori Mukai, Kei Takahashi, Aya Sugimoto, Naoto Osugi, Yu Higaki, Ryo
338 339 340 341 342 343	We thank all the collaborators who are cooperating in this first nationwide study of the Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI). The collaborators involved in the REX-GI study are as follows: Mitsuhiro Fujishiro (Nagoya University Graduate School of Medicine), Masashi Yamamoto, Dai Nakamatsu, Kaori Mukai, Kei Takahashi, Aya Sugimoto, Naoto Osugi, Yu Higaki, Ryo Tomita, Tatsuya Sakamoto, Emi Meren, Kazuki Aochi, Shinji Kuriki, Li-sa Chang, and
338 339 340 341 342 343 344	We thank all the collaborators who are cooperating in this first nationwide study of the Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI). The collaborators involved in the REX-GI study are as follows: Mitsuhiro Fujishiro (Nagoya University Graduate School of Medicine), Masashi Yamamoto, Dai Nakamatsu, Kaori Mukai, Kei Takahashi, Aya Sugimoto, Naoto Osugi, Yu Higaki, Ryo Tomita, Tatsuya Sakamoto, Emi Meren, Kazuki Aochi, Shinji Kuriki, Li-sa Chang, and Koji Fukui (Toyonaka Municipal Hospital), Yousuke Nakai (The University of Tokyo),
338 339 340 341 342 343 344 345	We thank all the collaborators who are cooperating in this first nationwide study of the Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI). The collaborators involved in the REX-GI study are as follows: Mitsuhiro Fujishiro (Nagoya University Graduate School of Medicine), Masashi Yamamoto, Dai Nakamatsu, Kaori Mukai, Kei Takahashi, Aya Sugimoto, Naoto Osugi, Yu Higaki, Ryo Tomita, Tatsuya Sakamoto, Emi Meren, Kazuki Aochi, Shinji Kuriki, Li-sa Chang, and Koji Fukui (Toyonaka Municipal Hospital), Yousuke Nakai (The University of Tokyo), Takahiro Suda (Kansai Rosai Hospital), Kazuhiro Matsunaga (Ishikawa Prefectural

3 4		
5 6 7	348	Cancer Research), Takumi Kanagawa, Yuichi Yoshida, Masafumi Naito (Suita
8 9	349	Municipal Hospital), Shuji Ishii (Osaka General Medical Center), Takuto Hikichi
10 11 12	350	(Fukushima Medical University School of Medicine), Naoki Fujimoto (Tane General
13 14 15	351	Hospital), Ikuya Miki (Hyogo Cancer Center), Yuzuru Tamaru (National Hospital
16 17	352	Organization Kure Medical Center and Chugoku Cancer Center), Hiromi Kataoka,
18 19 20	353	Kazuki Hayashi (Nagoya City University Graduate School of Medical Sciences), and
21 22	354	Hiroaki Shigoka (Toho University Ohashi Medical Center).
23 24 25	355	
26 27	356	Funding statement
28 29 30	357	This research received no specific grants from any funding agency in the public,
31 32 33	358	commercial or not-for-profit sectors.
34 35	359	
36 37 38	360	Publication and data sharing
39 40 41	361	After completion of the study, a main manuscript will be prepared to present the results
42 43 44	362	and will be submitted to a clinical journal for peer review. This study will ensure that the
45 46 47	363	public has access to the published data. A file containing the clean dataset used for the
48 49	364	final analysis to determine the main data of the study and an explanation of the
50 51 52	365	variables will be made publicly accessible in an anonymized format.
53 54	366	
55 56 57 58 59 60	367	Consent for publication

The principal investigators will form a publication committee, which will include key

members of this study, and the committee will grant authorship according to individual input. Investigators who do not qualify for authorship will be acknowledged by name in the final manuscript. **Conflicts of interest statement** None of the authors have any competing interests related to this research. Terez onz

BMJ Open

2		
4		
5		
6	376	Discussion
7 8		
9	377	Currently, the establishment of DRLs is an international requirement for protection from
10		
11	378	medical radiation. For diagnostic radiology, national and regional DRLs are usually set
12 13		
13	379	at the 75% percentile of the distribution of a typical sample dose ²⁶ . All physicians or
15		
16	380	medical staff who are involved in radiological imaging or procedures under fluoroscopic
17		
18 19	381	guidance should be familiar with the DRL process as a tool for optimizing protection. In
20		
21	382	addition, separate DRLs must be established for each country and/or region because
22		
23 24	383	the equipment and procedure protocols can vary among different regions ²⁶ . However,
25		
26	384	the amount of RE depends on the procedure complexity, patient anatomy, lesion
27		
28 29	385	characteristics, disease severity ¹¹ and type of fluoroscopic devices ²¹ ; thus, setting the
30		
31	386	upper limit of radiation use by applying uniform standards is difficult. Generally, DRLs
32		
33 34	387	are not dose limits and do not help distinguish between good and poor medical
35		
36	388	practices ²⁶ . Therefore, a high demand exists for a large amount of real-world evidence.
37		,
38 39	389	The 2015 Japan DRLs state that the methods for establishing DRLs not only include
40		
41	390	setting radiation dose levels but also includes determining the dose quantities and units
42		алан улаан алаан алаа
43 44	391	used to set the DRLs, thus standardizing the methodology for dose measurements,
44 45		
46	392	data collection and identification of the applications of DRLs ¹² .
47	002	
48 40	393	Unfortunately, most gastroenterologists are unfamiliar with not only DRLs but also
49 50	000	emontaliately, most gast centerologiste are amaninar with het only Dives but also
51	394	radiation protection because information on RE from gastrointestinal medical treatment
52	004	
53	395	is currently very scarce, and few RE standards, including DRLs, have been established
54 55	000	is currently very scalee, and rew rel standards, including Dres, have been established
56	396	worldwide. Given this background, the REX-GI study is planned as an observational,
57	000	wonamide. Given and background, the NEX-OFStudy is plainted as an observational,
58	397	nationwide study in Japan. Our results will help to promote radiation optimization and
59 60	007	
00		

Page 24 of 43

patient radiation protection in gastroenterology studies, such as digestive endoscopy,

and hepatobiliary and pancreatic procedures.

<text>

Table 1. Fluoroscopic system and	d units performing p	BMJ Open	uoroscopic guidar	omjopen-2019-033604 on 26		23
	Number of Hospital Beds		Fluoroscop	Feb		Fluoroscopy
		Company	Device model	Apparatus type	Year of introduction	Location
Toyonaka Municipal Hospital	613	Hitachi	Exavista	Over-tube	2016	Endoscopy
Kindai University	929	Hitachi	Curevista	Over-tubଙ୍ଗି	2017	Endoscopy
The University of Tokyo	1216	Hitachi	Curevista	<u>∃</u> Over-tub ∉	2009	Radiology
		Canon Toshiba	Exavista	Over-tube	2013	
		Canon Toshiba	Ultimax-I	Under-tube	2016	
Fukui Prefectural Hospital	880	Hitachi	Versiflex	Over-tube	2008	Endoscopy
Kansai Rosai Hospital	642	Canon Toshiba	Zexira	Over-tube	2011	Radiology
		Canon Toshiba	Ultimax-I	Under-tube	2017	
Osaka City University	891	Hitachi	Curevista	Over-tube	2011	Endoscopy
		Hitachi	Versiflex vista	Under-tube	2015	Endoscopy
Ishikawa Prefectural Central Hospital	639	Canon Toshiba	Drex-zx80	Over-tubey	2016	Endoscopy
Tonan Hospital	283	Hitachi	Curevista	می Over-tube	2013	Radiology
		Canon Toshiba	ZEXIRA	ठू Over-tube	2016	
			,	ted by copyright		

		BMJ Open		omjopen		
				omjopen-2019-03360		24
Japanese Foundation	686	Canon Toshiba	Ultimax-i	Under-tub	2016	Radiology
for Cancer Research				26 Fe		
Suita Municipal Hospital	431	Hitachi	Versiflex	Under-tub	2018	Endoscopy
Osaka Rosai Hospital	678	Hitachi	Exavista	Under-tube	2018	Radiology
Osaka General Medical Center	768	Hitachi	Curevista,	Over-tube	2018	Endoscopy
		Hitachi	Versiflex	ownld		
Fukushima Medical University	778	Canon Toshiba	Zexira	Over-tub	2012	Radiology
School of Medicine		Canon Toshiba	FPD1717	d from		
Hyogo Cancer Center	400	Hitachi	Curevista	Over-tube	2019	Endoscopy
Kitano Hospital	699	Hitachi	Versiflex	Under-tub	2017	Endoscopy
		Hitachi	Curevista	Over-tube		
Tane General Hospital	304	Hitachi	Exavista	Over-tub	2011	Radiology
Japanese Red Cross Medical	708	Hitachi	Curevista	Over-tube	2016	Radiology
Center				on A		
Kure Medical Center and	700	Hitachi	Exavista	Over-tube	2010	Endoscopy

Ultimax-I

Ultimax-I

Under-tub

y gue test Under-tube

rotected by copyright.

Endoscopy

Radiology

Chugoku Cancer Center

Nagoya City University Hospital

Toho University Ohashi Medical

Center

Canon Toshiba

Canon Toshiba

Page 27 of 43			BMJ Open		omjoper		
1 2 3		omjopen-2019-033604		25			
4 5 6 7	Osaka International Cancer Institute	500	Canon Toshiba	Ultimax-I		2017	Endoscopy
7 8 9	Gifu University Hospital	606	Shimadzu	C-Vision Safire	Under-tub	2004	Radiology
$ \begin{array}{r} 11 \\ 12 \\ 13 \\ 14 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 21 \\ 22 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 29 \\ 30 \\ 31 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 38 \\ 39 \\ 40 \\ 41 \\ 42 \\ 43 \\ 44 \\ 45 \\ \end{array} $	Osaka International Cancer Institute Gifu University Hospital		- http://bmjopen.bmj.c		st. Protected by copyright.		

0022019-033604 on 26 om

Table 2. Primary outcomes

Factors	Variables	Febr
Patients	Procedure type	February 2020. Dow
	• Age	20
	• Sex	Dow
Fluoroscopic system	 Fluoroscopic device (company, device model, r 	nanufacturing y ar)
	 Basic use setting: frame per second (FPS), rad 	
Radiation exposure	 Total fluoroscopy time (FT) (min) 	om h
	 Air-Kerma (AK) (mGy) 	ttp://
	 Dose-area product (DAP) (Gycm²) 	jop
	 Total number of roentgenography procedures 	ben.b
	 Radiation dose rate (RDR) (mGy/min) 	<u>m</u> i.
When the setting changes o	uring the procedure, we will record the basic setting.	om http://bmjopen.bmj.cdm/ on April 17, 2024 by guest. Protected by copyright.
		ğ

Table 3. Secondary outcomes

	BMJ Open 2019-033604 on 26 February outcomes 27
	27
	26 Fi
Table 3. Secondary	y outcomes
Procedures	Radiation exposure-related factors
ERCP	(A) Surgically altered gastrointestinal anatomy
	Billroth I reconstruction, Billroth II reconstruction, Roux-en-Y recons
	pancreaticoduodenectomy
	(B) Type of endoscope
	(C) Naïve papilla
	(D) Indications for ERCP (including suspicion) are classified into the following five categories:
	1) Choledocholithiasis (maximum diameter, number of stones, presence af cholangitis, tube exchange
	for the above diseases, treatment for choledocholithiasis with or without galloon catheter, basket
	catheter, crusher, etc.)
	2) Distant malignant bile duct stricture (papillary tumor, distal cholangiocarcinoma, pancreatic cancer,
	etc.)
	3) Proximal malignant bile duct stricture (Hilar cholangiocarcinoma, intra $\vec{\vec{p}}$ epatic cholangiocarcinoma,
	gallbladder cancer, etc.)
	4) Pancreatic duct examination (pancreas cancer, intraductal papillary mecinous neoplasm, etc.)
	5) Other diseases apart from those listed above (benign bile duct stricture, pancreatobiliary junction
	abnormality, etc.)
	(E) Total procedure time (min) *
	cot X
	copyright
	Francisco de la la contra de la c

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	ο
_	о

	BMJ Open
	n-2018
	BMJ Open pp. 2019-0336
	1) Cannulation time
	2) Treatment time
	(F) Experience of the high-volume endoscopist (HVE) or low-volume endosce
	(G) Facility scale: The number of ERCP procedures per year
	(H) Whether the fluoroscopic operator is inside or outside in the fluoroscopy Bom
	(I) Various treatments (endoscopic sphincterotomy, stone treatment, bile duce pancreatic stent, cytology,
	biopsy, naïve papilla, cannulation method, contrast agent, intubation time, first-use catheter, large balloon,
	crusher, drainage area or method, stent type used, cholangioscopy)
	(J) Sedation: Medication and the depth of the anesthesia ‡
Interventional EUS	(A) Indication for interventional EUS (EUS-guided hepaticogastrostomy (HGs)), choledochoduodenostomy
	(CDS), cyst drainage (CD), antegrade treatment (AG), rendezvous technique (RV), pancreatic duct drainag
	(PD)
	(B) Total procedure time‡
	1) Endoscope insertion time
	2) Treatment time
	(C) Facility scale: The number of EUS interventions per year, the number of \vec{E} US-guided fine-needle
	aspiration (FNA) procedures per year
	(D) Double stenting (presence or absence of duodenal stenosis)
	(E) Device
	(E) Device est. Protected (F) Scope position est. Protected (G) Sedation: Medication and the depth of anesthesia opyright
	(G) Sedation: Medication and the depth of anesthesia

Page 31 of 43

0	\sim
- 7	ч
_	0

	BMJ Open g
	an-20
	919 9-0
	BMJ Open 907-2019-03360
Balloon-assisted	(A) Disease indicating balloon-assisted enteroscopy
enteroscopy	1) Hemostatic or bleeding confirmation
	2) Crohn's disease
	3) Small intestine tumor examination
	4) Others
	(B) Insertion site: perioral or transanal
	1) Hemostatic or bleeding confirmation202) Crohn's disease3) Small intestine tumor examination4) Others(B) Insertion site: perioral or transanal(C) Insertion length (cm)
	(D) Total procedure time (min)
Enteral metallic stent	
placement	(A) Stent location Image: Comparison of the second sec
	2) Gastro-duodenum (Above pylorus/Trans pylorus /Below pylorus)
	3) Colon stent (Right/Left/Rectum)
	(B) Total procedure time (min) §
	1) Endoscope insertion time
	2) Treatment time
Enteral ileus tube	(A) Disease indicating ileus tube
placement	(B) Intranasal ileus tube insertion for ileal obstruction or transanal ileus tube Resertion for malignant colonic
	obstruction
	1) Tube insertion length for peroral ileus tube placement (cm)
	2) The occlusion site for the transanal tube (Right/Left/Rectum) (D) Total procedure time (min) §
	(D) Total procedure time (min) §
	рул Ig

Protected by copyright

ERCP: endoscopic retrograde cholangiopancreatography

 * Cannulation time is defined as the time from endoscope insertion until successful biliary cannulation, and treatment time is defined as the time from successful biliary cannulation until the scope is removed from the patient. The total procedure time is defined as the time from endoscope insertion until the scope is removed from the patient (cannulation time +treatment time).

 \ddagger Depth of anesthesia is divided into 3 levels based on the Richmond Agitation-Sedation Scale (RASS) Ramsay Scale, and Sedation-Agitation Scale (SAS): good, poor, and very bad. The good level is defined as RASS score: $-5 \sim -1$, SAS score: $1 \sim 3$, and Ramsay score: $3 \sim 6$ equivalent, without additional unplanned doses. The poor level is defined as RASS score: $2 \sim -1$, SAS score: $4 \sim 5$, and Ramsay score: $1 \sim 2$, without physical restraint but with unplanned doses. The very bad level is defined as requiring physical restraint with a force considered dangerous, RASS score: +2 to +4, and SAS score: 6 to 7 regardless of Ramsay score.

+ HVE: Endoscopists with more than 200 ERCP results and who have been involved in ERCP for over 10 years. LVE: Non-HVE endoscopists who perform ERCP.

 \ddagger Endoscope insertion time is defined as the time from endoscope insertion until the initial EUS-guided needle puncture, and treatment time is defined as the time from initial EUS-guided needle puncture until the scope is removed from the patient. The total procedure time is defined as the time from endoscope insertion until the scope is removed from the patient (endoscope insertion time +treatment time).

‡Endoscope insertion time is defined as the time from endoscope insertion until initial guidewire exploration, and treatment time is defined as the time from initial guidewire exploration until the scope is removed from the patient. The total procedure time is defined as the time from endoscope insertion until the scope is removed from the patient (endoscope insertion time +treatment time).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Figure legends

Figure 1. The participating hospitals in this study.

References

- Henry MF, Maender JL, Shen Y, et al. Fluoroscopy-induced chronic radiation dermatitis: a report of three cases. *Dermatol Online J* 2009;15(1):3. [published Online First: 2009/03/14]
- NCRP Commentary No. 27: Implications of Recent Epidemiologic Studies for the Linear-Nonthreshold Model and Radiation Protection 2018 [Available from: https://ncrponline.org/wp-

content/themes/ncrp/Pub_announcements/Commentary_No27_overview.pdf accessed July 9th, 2019.

 Park TH, Eichling JO, Schechtman KB, et al. Risk of radiation induced skin injuries from arrhythmia ablation procedures. *Pacing Clin Electrophysiol* 1996;19(9):1363-9. doi: 10.1111/j.1540-8159.1996.tb04216.x [published Online First: 1996/09/01]

- 4. de González AB, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. *The Lancet* 2004;363(9406):345-51. doi: 10.1016/s0140-6736(04)15433-0
- 5. Jaffe D, Bowden GT. Ionizing radiation as an initiator: effects of proliferation and promotion time on tumor incidence in mice. *Cancer Res* 1987;47(24 Pt 1):6692-6.
- Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ* 2013;346:f2360. doi: 10.1136/bmj.f2360

7. Kho	ramian D, Sistai	ni S, Hejazi P. Establisi	nment of diagnos	stic reference levels aris	ing
	from common	CT examinations in	Semnan Count	y, Iran. <i>Polish Journal</i>	of
	Medical Physic	cs and Engineering 20	19;25(1):51-55.	doi: 10.2478/pjmpe-20	19-
	0008				
8. Ra	diological prote	ection and safety in	medicine. A re	eport of the Internatio	nal
	Commission of	n Radiological Protecti	on. <i>Ann ICRP</i> 1	996;26(2):1-47. [publisł	ned
	Online First: 19	996/01/01]			
9. The	e 2007 Recom	mendations of the Ir	nternational Cor	nmission on Radiolog	ical
	Protection. IC	CRP publication 103	. Ann ICRP	2007;37(2-4):1-332.	doi:
	10.1016/j.icrp.2	2007.10.003 [published	l Online First: 20	07/12/18]	
10. ICF	RP Publication 1	105. Radiation protection	on in medicine. A	Ann ICRP 2007;37(6):1-	63.
	doi: 10.1016/j.i	crp.2008.08.001 [publi	shed Online Firs	t: 2008/09/03]	
11. Va	no E, Miller DL	., Martin CJ, et al. ICI	RP Publication 2	35: Diagnostic Refere	nce
	Levels in	Medical Imaging.	Ann ICRP	2017;46(1):1-144.	doi:
	10.1177/01466	645317717209 [publish	ed Online First:	2017/10/27]	
12. Dig	gnostic Referen	ce Levels Based on La	atest Surveys in	Japan -Japan DRLs 20	15-
	2015	[Available	from:	http://www.radher.jp	<u>o/J-</u>
	RIME/report/D	RLhoukokusyoEng.pdf	accessed July §	9th, 2019.	
13. Ha	rt D, Wall BF. U	IK population dose from	n medical X-ray	examinations. Eur J Ra	diol
	2004;50(3):285	5-91. doi: 10.1016/S0)720-048X(03)0()178-5 [published Onl	line
	First: 2004/05/	18]			
14. Du	imonceau JM, (Garcia-Fernandez FJ,	Verdun FR, et	al. Radiation protectior	n in

 digestive endoscopy: European Society of Digestive Endoscopy (ESGE) guideline. *Endoscopy* 2012;44(4):408-21. doi: 10.1055/s-0031-1291791 [published Online First: 2012/03/23]


- 15. Hayashi S, Takenaka M, Hosono M, et al. Radiation exposure during image-guided endoscopic procedures: The next quality indicator for endoscopic retrograde cholangiopancreatography. *World Journal of Clinical Cases* 2018;6(16):1087-93. doi: 10.12998/wjcc.v6.i16.1087
- 16. Hayashi S, Takenaka M, Hosono M, et al. Radiation exposure during image-guided endoscopic procedures: The next quality indicator for endoscopic retrograde cholangiopancreatography. *World J Clin Cases* 2018;6(16):1087-93. doi: 10.12998/wjcc.v6.i16.1087 [published Online First: 2019/01/08]
- 17. Adler DG, Lieb JG, 2nd, Cohen J, et al. Quality indicators for ERCP. Gastrointestinal endoscopy 2015;81(1):54-66. doi: 10.1016/j.gie.2014.07.056 [published Online First: 2014/12/07]
- Matsuda K, Tanaka K, Fujishiro M, et al. Design paper: Japan Endoscopy Database (JED): A prospective, large database project related to gastroenterological endoscopy in Japan. *Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society* 2018;30(1):5-19. doi: 10.1111/den.12964 [published Online First: 2017/09/15]
- 19. Diagnostic reference levels in medical imaging: review and additional advice. *Ann ICRP* 2001;31(4):33-52. [published Online First: 2003/04/11]
- 20. Lynskey GE, 3rd, Powell DK, Dixon RG, et al. Radiation protection in interventional

BMJ Open

radiology: survey results of attitudes and use. Journal of vascular and
interventional radiology : JVIR 2013;24(10):1547-51 e3. doi:
10.1016/j.jvir.2013.05.039 [published Online First: 2013/07/24]
21. Hayashi S, Nishida T, Matsubara T, et al. Radiation exposure dose and influencing
factors during endoscopic retrograde cholangiopancreatography. PloS one
2018;13(11):e0207539. doi: 10.1371/journal.pone.0207539 [published Online
First: 2018/11/20]
22. Strahlenschutz Bf. Bekanntmachung der aktualisierten diagnostischen
Referenzwerte für diagnostische und interventionelle Röntgenanwendungen
Vom 22. Juni 2016
2016 [Available from: <u>https://www.klinikum.uni-</u>
heidelberg.de/fileadmin/strahlenschutz/linkimages/PDF/DRW-XRay-2016-07-
15.pdf accessed Nov 9 2019.
23. Hayashi S, Nishida T, Shimakoshi H, et al. Mo2020 Novel Processing Engine for X-
Ray Fluoroscopic Images (Faice-V Ns1) Can Reduce Radiation Exposure in the
Procedure of ERCP But Keep the Quality of Images. Gastrointestinal endoscopy
2017;85(5):AB518. doi: 10.1016/j.gie.2017.03.1207
24. Hayashi S, Higaki Y, Tomita R, et al. 940 Disease Site and Processing Engine Affect
Radiation Exposure Dose during Ercp. Gastrointestinal endoscopy
Radiation Exposure Dose during Ercp. <i>Gastrointestinal endoscopy</i> 2018;87(6):AB137. doi: 10.1016/j.gie.2018.04.1348

GUIDED DRAINAGE (EUS-BD/EUS-PD/EUS-CD). *Gastrointestinal endoscopy* 2019;89(6):AB444-AB45. doi: 10.1016/j.gie.2019.03.1247

26. Vassileva J, Rehani M. Diagnostic reference levels. AJR Am J Roentgenol 2015;204(1):W1-3. doi: 10.2214/AJR.14.12794 [published Online First: 2014/12/30]



Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

30				
31				Page
32 33			Reporting Item	Number
34 35	Administrative			
36 37 38	information			
38 39 40	Title	<u>#1</u>	Descriptive title identifying the study design, population,	1
40 41 42			interventions, and, if applicable, trial acronym	
43 44 45	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	6, 11
46 47 48 49	Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	6, 11
50 51	Protocol version	<u>#3</u>	Date and version identifier	16
52 53 54	Funding	<u>#4</u>	Sources and types of financial, material, and other support	17
54 55 56	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	15
57 58 59	responsibilities: contributorship			
60	Fc	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6	Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	N.A.
7 8 9 10 11 12 13 14 15	Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N.A.
16 17 18 19 20 21 22 23	Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	12, 14
24 25	Introduction			
26 27	Background and	<u>#6a</u>	Description of research question and justification for undertaking	8-10
28 29 30 31	rationale		the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	
32 33 34 35 36	Background and rationale: choice of comparators	<u>#6b</u>	Explanation for choice of comparators	9
37 38	Objectives	<u>#7</u>	Specific objectives or hypotheses	9-10
39 40 41 42 43 44 45	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	11
46 47	Methods:			
48 49	Participants,			
50 51 52	interventions, and outcomes			
52 53 54 55 56 57 58	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	12
59 60		For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open: first published as 10.1136/bmjopen-2019-033604 on 26 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

1 2 3 4 5	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	12
6 7 8 9	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	N.A.
9 10 11 12 13 14	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	N.A.
15 16 17 18 19	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	N.A.
20 21 22 23	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N.A.
24 25 26 27 28 29 30 31 32 33	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	13
34 35 36 37 38	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	15
39 40 41 42 43	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
44 45 46 47	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	14
48 49	Methods: Assignment			
50 51	of interventions (for			
52 53	controlled trials)			
54	Allocation: sequence	#16a	Method of generating the allocation sequence (eg, computer-	N.A.
55 56 57 58 59 60	generation		generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

Page 4	3 of 43		BMJ Open	
1 2 3			provided in a separate document that is unavailable to those who enrol participants or assign interventions	
4 5 6 7 8 9	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	N.A.
10 11 12 13	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	N.A.
14 15 16 17 18 19	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N.A.
20 21 22 23 24	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N.A.
25 26	Methods: Data			
27 28	collection, management, and			
29 30	analysis			
31 32 33 34 35 36 37 38 39 40 41 42	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14
43 44 45 46 47	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
48 49 50 51 52 53 54	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	15
55 56 57 58 59 60	Statistics: outcomes	<u>#20a</u> or peer rev	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	14

1 2 3	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N.A.
4 5 6 7 8 9	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non- adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	15
10 11	Methods: Monitoring			
12 13 14 15 16 17 18 19 20 21	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	15
22 23 24 25 26	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	15
27 28 29 30 31	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	N.A.
32 33 34 35 36 37	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N.A.
38 39	Ethics and			
40 41	dissemination			
42 43 44	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	15
45 46 47 48 49 50 51	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	N.A.
52 53 54 55 56 57 58 59	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	15
60	Fo	r peer rev	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5	Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N.A.
6 7 8 9 10	Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
11 12 13 14	Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	17, 18
15 16 17 18 19	Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17
20 21 22 23	Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N.A.
24 25 26 27 28 29 30 31	Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14
32 33 34 35	Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	18
36 37 38 39	Dissemination policy: reproducible research	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N.A.
40 41	Appendices			
42 43 44 45	Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and authorised surrogates	N.A.
46 47 48 49 50	Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N.A.
51 52 53 54 55 56 57 58		st can b	stributed under the terms of the Creative Commons Attribution Licer e completed online using <u>https://www.goodreports.org/</u> , a tool made ation with <u>Penelope.ai</u>	
59	F -		view entry http://hypionen.hypionen.kypicena/cite/elegyt/avidelines/http:/	

BMJ Open

A Multicenter Prospective Observational Study Protocol for Radiation Exposure from Gastrointestinal Fluoroscopic Procedures (REX-GI study)

lournali	RM1 Onen
Journal:	
Manuscript ID	bmjopen-2019-033604.R2
Article Type:	Protocol
Date Submitted by the Author:	20-Dec-2019
Complete List of Authors:	Nishida, Tsutomu ; Toyonaka Municipal Hospital, Department of Gastroenterology Hayashi, Shiro; Toyonaka Municipal Hospital, Department of Gastroenterology; Kento Hayashi Clinic, Department of Gastroenterology and Internal Medicine Takenaka, Mamoru ; Kindai University, Department of Gastroenterology Hosono, Makoto ; Kindai University, Department of Radiology Kogure, Hirofumi; The University of Tokyo, Department of Gastroenterology Hasatani, Kenkei ; Fukui Prefectural Hospital, Department of Gastroenterology Yamaguchi, Shinjiro ; Kansai Rosai Hospital, Department of Gastroenterology and Hepatology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Maruyama, Hirotsugu ; Osaka City University, Department of Gastroenterology Ihara, Hideyuki ; Tonan Hospital, Department of Gastroenterology Ihara, Hideyuki ; Cancer Institute Hospital, Japanese Foundation for Cancer Research, Department of Gastroenterology Nagaike, Koji ; Suita Municipal Hospital, Department of Gastroenterology and Hepatology, Yamada, Takuya ; Osaka Rosai Hospital, Department of Gastroenterology and Hepatology, Yakushijin, Takayuki ; Osaka General Medical Center, Department of Gastroenterology and Hepatology, Yakushijin, Takayuki ; Sushima Medical University School of Medicine, Department of Gastroenterology Tsumura, Hidetaka ; Hyogo Cancer Center, Department of Gastroenterology and Hepatology, Kurita, Akira ; Kitano Hospital, Department of Gastroenterology and Hepatology, Digestive Disease Center Asai, Satoshi ; Tane General Hospital, Department of Gastroenterology and Hepatology, Digestive Disease Center Asai, Satoshi ; Tane General Hospital, Department of Gastroenterology Ito, Yukiko ; Japanese Red Cross Medical Center, Department of Gastroenterology Hori, Yasuki ; Nagoya City University Graduate School of Medical Sciences Department of Gastroenterology and Metabolism

	Maetani, Iruru ; Toho University Ohashi Medical Center, Division of Gastroenterology and Hepatology, Department of Internal Medicine Ikezawa, Kenji ; Osaka International Cancer Institute, Department of Hepatobiliary and Pancreatic Oncology Iwashita, Takuji ; Gifu University Hospital, First Department of Interna Medicine Matsumoto, Kengo; Toyonaka Municipal Hospital, Department of Gastroenterology Inada, Masami ; Toyonaka Municipal Hospital, Department of Gastroenterology
Primary Subject Heading :	Gastroenterology and hepatology
Secondary Subject Heading:	Radiology and imaging, Public health, Research methods
Keywords:	Radiation Exposure, Diagnostic Reference Levels, ERCP, Gastrointestin Fluoroscopic Procedure, Endoscopy < GASTROENTEROLOGY

SCHOLARONE[™] Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2019-033604 on 26 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

1	A Multicenter Prospective Observational Study Protocol for Radiation Exposure
2	from Gastrointestinal Fluoroscopic Procedures (REX-GI study)
3	
4	Tsutomu Nishida ¹⁾ , Shiro Hayashi ¹⁾²⁾ , Mamoru Takenaka ³⁾ , Makoto Hosono ⁴⁾ , Hirofumi
5	Kogure ⁵⁾ , Kenkei Hasatani ⁶⁾ , Shinjiro Yamaguchi ⁷⁾ , Hirotsugu Maruyama ⁸⁾ , Hisashi
6	Doyama ⁹⁾ , Hideyuki Ihara ¹⁰⁾ , Toshiyuki Yoshio ¹¹⁾ , Koji Nagaike ¹²⁾ , Takuya Yamada ¹³⁾ ,
7	Takayuki Yakushijin ¹⁴⁾ , Tadayuki Takagi ¹⁵⁾ , Hidetaka Tsumura ¹⁶⁾ , Akira Kurita ¹⁷⁾ ,
8	Satoshi Asai ¹⁸⁾ , Yukiko Ito ¹⁹⁾ , Toshio Kuwai ²⁰⁾ , Yasuki Hori ²¹⁾ , Iruru Maetani ²²⁾ , Kenji
9	Ikezawa ²³⁾ , Takuji Iwashita ²⁴⁾ , Kengo Matsumoto ¹⁾ , Masami Inada ¹⁾
10	
11	1) Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Osaka,
12	Japan
13	2) Department of Gastroenterology and Internal Medicine, Kento Hayashi Clinic,
14	Suita, Osaka, Japan
15	3) Department of Gastroenterology and Hepatology, Kindai University, Faculty of
16	Medicine, Osaka-Sayama, Osaka, Japan
17	4) Department of Radiology, Kindai University Faculty of Medicine, Osaka-Sayama,
18	Osaka, Japan
19	5) Department of Gastroenterology, Graduate School of Medicine, The University of
20	Tokyo, Tokyo, Japan
21	6) Department of Gastroenterology, Fukui Prefectural Hospital, Fukui, Fukui, Japan
22	7) Department of Gastroenterology and Hepatology, Kansai Rosai Hospital,

- -		
2		
3		
4		
5	00	
6	23	Amagasaki, Hyogo, Japan
7		
8	24	8) Department of Gastroenterology, Osaka City University, Graduate School of
9	21	of Department of Cabacemerology, Coaka only envelony, Cradade Concer of
10		
11	25	Medicine, Osaka, Osaka, Japan
12		
13	26	0) Department of Castroonterology, Johikawa Profestural Central Heapital, Kanazawa
14	20	9) Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa,
15		
16	27	Ishikawa, Japan
17		
18	00	10) Department of Ocetro enterplany. Tenen Lleanitel, Conners, Lleidveide, Janen
19	28	10) Department of Gastroenterology, Tonan Hospital, Sapporo, Hokkaido, Japan
20		
21	29	11) Department of Gastroenterology, Cancer Institute Hospital, Japanese Foundation
22		,
23	00	
24	30	for Cancer Research, Ariake, Tokyo, Japan
25		
26	31	12) Department of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka,
27		
28	20	
29	32	Japan
30		
31	33	13) Department of Gastroenterology and Hepatology, Osaka-Rosai Hospital,
32		
33	34	Sakai, Osaka, Japan
34	94	Saka, Sapan
35		
36	35	14) Department of Gastroenterology and Hepatology, Osaka General Medical Center,
37		
38	36	Osaka, Osaka, Japan
39 40	00	
40 41		
41	37	15) Department of Gastroenterology, Fukushima Medical University School of
42		
44	38	Medicine, Fukushima, Japan
45		
46	39	16) Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan
47		
48	40	
49	40	17) Department of Gastroenterology and Hepatology, Digestive Disease Center, Kitano
50		
51		
52	41	Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Osaka, Japan
53		
54		
55	42	18) Department of Gastroenterology, Tane General Hospital, Osaka, Osaka, Japan
56		
57	43	19) Department of Gastroenterology, Japanese Red Cross Medical Center, Tokyo,
58		, ,
59		
60		

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

BMJ Open
3
Japan
20) Department of Gastroenterology, National Hospital Organization, Kure Medical
Center and Chugoku Cancer Center, Kure, Japan
21) Department of Gastroenterology and Metabolism, Nagoya City University Graduate
School of Medical Sciences, Nagoya, Japan
22) Division of Gastroenterology and Hepatology, Department of Internal
Medicine, Toho University Ohashi Medical Center, Tokyo, Japan
23) Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer
Institute, Osaka, Osaka, Japan
24) First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan
Address all correspondence to: Tsutomu Nishida, M.D.
Department of Gastroenterology, Toyonaka Municipal Hospital
4-14-1 Shibahara, Toyonaka, Osaka 560-8565 Japan
Email: tnishida.gastro@gmail.com
Tel: +81-6-6843-0101
Email addresses: Tsutomu Nishida: tnishida.gastro@gmail.com, Shiro Hayashi:
hayashishiro1976@yahoo.co.jp, Mamoru Takenaka: mamoxyo45@gmail.com, Makoto
Hosono: hosono@med.kindai.ac.jp, Hirofumi Kogure: kogureh-tky@umin.ac.jp, Kenkei

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

65	Hirotsugu Maruyama: hiromaruyama99@gmail.com, Hisashi Doyama:
66	doyama.134@gmail.com, Hideyuki Ihara: <u>h-ihara@tonan.gr.jp</u> , Toshiyuki Yoshio:
67	toshiyuki.yoshio@jfcr.or.jp, Koji Nagaike: nagaike.koji@gmail.com, Takuya Yamada:
68	<u>yamtak1973@gmail.com</u> , Takayuki Yakushijin: <u>yakushijin@gh.opho.jp</u> , Tadayuki
69	Takagi: <u>daccho@fmu.ac.jp</u> , Hidetaka Tsumura: <u>h.tsumura@hp.pref.hyogo.jp</u> , Akira
70	Kurita: kuritaaki1976@gmail.com, Satoshi Asai: bonyaritetsu1226@hotmail.co.jp,
71	Yukiko Ito: yukikomd1224@gmail.com, Toshio Kuwai: toshiokuwai@gmail.com,
72	Yasuki Hori: yhori@med.nagoya-cu.ac.jp , Iruru Maetani: mtnir50637@med.toho-
73	<u>u.ac.jp</u> , Kenji Ikezawa: <u>ikezawa-ke@mc.pref.osaka.jp</u> , Takuji Iwashita:_
74	takuji@w7.dion.ne.jp, Kengo Matsumoto: ken5@gh.med.osaka-u.ac.jp, Masami Inada
75	inada-intoyo@chp.toyonaka.osaka.jp
76	
77	Word count: 2804 words
78	
79	Keywords: Radiation Exposure, Diagnostic Reference Levels, ERCP, Gastrointestinal
80	Fluoroscopic Procedure, Endoscopy.
81	

BMJ Open

2 3 4		
5 6 7	82	ABSTRACT
8 9	83	INTRODUCTION: Recently, the use of various endoscopic procedures under X-ray
10 11 12	84	fluoroscopic guidance, such as endoscopic retrograde cholangiopancreatography
13 14 15	85	(ERCP), interventional endoscopic ultrasonography (EUS), enteral endoscopy, and
16 17	86	stenting, has been rapidly increasing because of the minimally invasive nature of these
18 19 20	87	procedures compared to that of surgical intervention. With the spread of computed
21 22	88	tomography and fluoroscopic interventions, including endoscopic procedures under X-
23 24 25	89	ray guidance, high levels of radiation exposure (RE) from medical imaging have led to
26 27	90	major concerns throughout society. However, information about RE related to these
28 29 30	91	image-guided procedures in gastrointestinal endoscopy is scarce, and the RE
31 32 33	92	reference levels have not been established. The aim of this study is to prospectively
34 35	93	collect the actual RE dose and to help establish diagnostic reference levels (DRLs) in
36 37 38	94	the field of gastroenterology in Japan.
39 40	95	METHODS AND ANALYSIS: This study is a multicenter, prospective observational
41 42 43	96	study that is being conducted to collect the actual RE from treatments and diagnostic
44 45	97	procedures, including ERCP, interventional EUS, balloon-assisted enteroscopy, enteral
46 47 48	98	metallic stent placement and enteral tube placement. We will measure the total
49 50 51 52 53 54 55	99	fluoroscopy time (FT, min), the total dose-area product (DAP, Gycm ²) and air-kerma
	100	(AK, mGy) of those procedures. Because we are collecting the actual RE data and
	101	identifying the influential factors through a prospective, nationwide design, this study
56 57 58	102	will provided guidance regarding the DRLs of ERCP, interventional EUS, balloon-
59 60	103	assisted enteroscopy, enteral metallic stent placement and enteral tube placement.

Page 8 of 42

-

104	ETHICS AND DISSEMINATION: This trial (Radiation EXposure from GastroIntestinal
105	fluoroscopic procedures: REX-GI study) was registered with the UMIN Clinical Trials
106	Registry at http://www.umin.ac.jp/ctr/ under number UMIN000036525 (registered 1
107	May 2019). Approval was obtained from the Institutional Review Board of Toyonaka
108	Municipal Hospital (2019-02-04). The need for informed consent will be waived via the
109	opt-out method of each hospital website.
110	
111	

	7

2 3 4			
5 6 7	112	Str	engths and limitations of this study
8 9	113	•	The large, multicenter, nationwide dataset of radiation exposure doses for
10 11 12	114		gastrointestinal fluoroscopic procedures in gastrointestinal endoscopy gathered in
13 14 15	115		this study will serve as a basis for the development of diagnostic reference levels in
16 17	116		Japan.
18 19 20	117	•	Gastrointestinal fluoroscopic procedures have been rapidly increasing in number
21 22	118		and complexity, but there are still not enough available local and national DRLs in
23 24 25	119		gastrointestinal endoscopy units.
26 27	120	•	These data may not be valid for old models of fluoroscopic systems because this
28 29 30	121		study will include data from fluoroscopic systems with available radiation data.
31 32	122		
33 34 35			
36 37			
38 39 40			
41 42 43			
44 45			
46 47 48			
49 50			
51 52 53			
55 55			
56 57			
58 59 60			

123	INTRODUCTION
-----	--------------

		BMJ Open
		8
12	23	INTRODUCTION
12	24	Medical radiation is widely used in both medical imaging and radiation treatment. In
12	25	medical imaging, fluoroscopy employs radiation to show a continuous X-ray image on a
12	26	monitor and plays a major role in the daily practices of gastroenterology, digestive
12	27	endoscopy, and hepatobiliary and pancreatic studies. Radiological medical imaging
12	28	has both benefits and drawbacks for patients. The latter is split into two types:
12	29	deterministic risks ¹ , determined by the threshold dose, as represented by skin injury,
13	30	and stochastic risks, determined by a linear no-threshold model, such as the cancer
13	31	risk ² . There have been some reports on radiation-induced skin injury in cardiology and
13	32	interventional radiology (IVR) ³ , but reports from gastrointestinal endoscopy units are
13	33	rare. However, all medical staff in gastrointestinal endoscopy units need to have
13	34	correct knowledge of the appropriate use of medical radiation. Historically, the use of
13	35	medical radiation has rapidly increased since the 1990s with the spread of computed
13	36	tomography (CT), and the radiation-associated cancer risk was recognized in the same
13	37	period, even when the doses of radiation were small 456 . In particular, the use of CT
13	38	has increased approximately 12-fold in the United Kingdom and more than 20-fold in
13	39	the United States in the last 25 years ⁷ .
14	40	The International Atomic Energy Agency (IAEA), the International Commission on
14	41	Radiological Protection (ICRP), the United Nations Scientific Committee on the Effects
14	42	of Atomic Radiation (UNSCEAR), and other radiological societies have been
14	43	attempting to manage medical radiation exposure (RE) according to the "as low as
14	44	reasonably achievable" (ALARA) principle by establishing diagnostic reference levels

Page 11 of 42

1

BMJ Open

1 2	
3	
4 5	
6	
7 8	
9	
10 11	
12	
13	
14 15	
16	
17 18	
19	
20 21	
22	
23 24	
25	
26 27	
28	
29 30	
30 31	
32	
33 34	
35	
36 37	
38	
39 40	
41	
42 43	
44	
45 46	
40 47	
48 49	
49 50	
51 52	
53	
54 55	
55 56	
57	
58 59	
60	

145	(DRLs) to optimize protection from medical radiation. The concept of DRLs was first
146	introduced by the ICRP 73 ⁸ in 1996. Then, the ICRP emphasized the important role of
147	DRLs as a tool for optimizing patient protection ^{9 10} . Accordingly, the ICRP set specific
148	target levels for various X-ray-related procedures in 2007 ⁹ . This movement of setting
149	DRLs has been led by radiation-related societies in each region, although the
150	movement has mainly been driven by Western countries. The ICRP 135 recommends
151	that all individuals who are involved in patient procedures with the risk of medical
152	exposure should be familiar with the DRL process as a tool for optimizing protection ¹¹ .
153	DRLs are now widely accepted in not only Western countries but also Japan (Japan
154	DRLs 2015) ¹² , and DRLs have become the global standard for all procedures that use
155	ionizing radiation. Legislation has made it mandatory to establish and record DRLs in
156	Europe, but that is not the case worldwide. The introduction of DRLs in the UK
157	achieved a reduction of approximately 50% in the radiation dose in typical X-ray
158	examinations over 15 years ¹³ . However, there is still not enough available data on RE
159	for gastrointestinal fluoroscopic procedures, such as endoscopic retrograde
160	cholangiopancreatography (ERCP), interventional endoscopic ultrasonography (EUS),
161	small bowel endoscopy, and enteral stent placement; these techniques are still being
162	developed and have recently been used with increasing frequency ^{14 15} .
163	Our gastroenterologists and endoscopists are still unfamiliar with the DRL concept.
164	Among the guidelines developed by gastrointestinal endoscopy associations, the 2012
165	European Gastrointestinal Endoscopy Society (ESGE) guidelines for radiation

Page 12 of 42

BMJ Open

166	protection state that the entrance skin dose (ESD; approximately equivalent to air-
167	kerma in this study) and kerma-area product (KAP; approximately equivalent to the
168	dose-area product (DAP) in this study) during diagnostic and therapeutic ERCP are 55-
169	347 mGy and 3-115/8-333 Gycm ² , respectively, although information regarding the
170	DRLs of ERCP is limited because this statement is based on only approximately 600
171	cases of ERCP in 7 reports ¹⁴ . No guidelines on RE from the American Society for
172	Gastrointestinal Endoscopy (ASGE) exist, but the ASGE recommends measuring and
173	documenting fluoroscopy time (FT) and radiation dose in all ERCP procedures as a
174	quality indicator (level of evidence: 2C) ¹⁶ . Although no guidelines for exposure have
175	been developed by the Japan Gastroenterological Endoscopy Society (JGES), a
176	description of FT exists in the item regarding ERCP in the Japan Endoscopy Database
177	(JED) ¹⁷ , which is scheduled to be implemented as a nationwide endoscopic survey in
178	2020.
179	Recently, various endoscopic procedures performed under fluoroscopic guidance are
180	rapidly increasing in popularity in gastrointestinal endoscopy units, where the aim is not
181	only diagnosis but also therapeutic intervention. The ICRP recommends that DRLs
182	should be used to manage patient doses during both diagnostic and interventional
183	procedures. There is difficulty in applying the DRL concept to interventional procedures
184	because the RE level depends on the complexity of the procedure and the individual

clinical circumstances ^{10 18 19}. There have been attempts to establish DRLs for IVR

procedures, where grouping by disease site may help minimize the wide distribution of RE 20 21.

The Japanese DRLs were established on a basis of a survey and released in 2015; these guidelines defined the DRL value for fluoroscopically guided interventional procedures as a fluoroscopic radiation dose rate (interventional reference point dose rate) of 20 mGy/min¹². However, it did not include information for specific procedures in the field of gastroenterology ¹². Therefore, we aim to prospectively collect actual RE data and identify the influential factors, such as disease site, in this REX-GI study and to establish DRLs for the following interventional procedures in gastrointestinal endoscopy units: ERCP, interventional EUS, balloon-assisted enteroscopy, enteral metallic stent placement and enteral tube placement.

	197	METHODS AND ANALYSIS
	198	Aims
0 1 2	199	The primary aim of this nationwide, prospective study is to collect actual data on RE
3 4	200	and identify the factors affecting RE during treatments and diagnostic procedures
5 6 7	201	under different types of fluoroscopic guidance for gastroenterology procedures,
8 9 0	202	including the gastrointestinal, hepatobiliary and pancreatic fields, to serve as a basis
1 2	203	for the establishment of DRLs in Japan.
3 4 5	204	
6 7	205	Design
8 9 0	206	This is a multicenter, prospective observational cohort study of consecutive patients
1 2	207	undergoing the following 5 treatments and diagnostic procedures under fluoroscopic
3 4 5	208	guidance in the field of gastroenterology: 1) ERCP, 2) interventional EUS, 3) balloon-
6 7	209	assisted enteroscopy, 4) enteral metallic stent placement; and 5) enteral tube
8 9 0	210	placement. We will examine the procedure time (min), total FT (min), AK (mGy), DAP
1 2	211	(Gycm ²), total number of roentgenography procedures, and radiation dose rate (RDR)
3 4 5	212	(mGy/min) during the procedures. The participating clinicians will manage patients
6 7	213	according to the usual clinical practice, and the patients will undergo the above 5
8 9 0	214	procedures. For the analysis, all data, including the related variables and outcome data
1 2	215	(Tables 1 and 2), will be collected for all patients. The study (Radiation EXposure from
3 4 5	216	GastroIntestinal fluoroscopic procedures: REX-GI study) was registered with the UMIN
6 7	217	Clinical Trials Registry at http://www.umin.ac.jp/ctr/ under the number UMIN000036525
8 9 0	218	(registered 1 May 2019).

3 4		
5 6 7	219	
8 9 10	220	Setting
11 12	221	The study will be conducted at 7 university hospitals, 4 cancer centers, 9 general
13 14 15	222	hospitals and 2 municipal hospitals in Japan. The participating hospitals are Toyonaka
16 17	223	Municipal Hospital, Kindai University, the University of Tokyo, Fukui Prefectural
18 19 20	224	Hospital, Kansai Rosai Hospital, Osaka City University, Ishikawa Prefectural Central
20 21 22	225	Hospital, Tonan Hospital, Japanese Foundation for Cancer Research, Suita Municipal
23 24 25	226	Hospital, Osaka Rosai Hospital, Osaka General Medical Center, Fukushima Medical
25 26 27	227	University School of Medicine, Hyogo Cancer Center, Kitano Hospital, Tane General
28 29 20	228	Hospital, Japanese Red Cross Medical Center, Kure Medical Center and Chugoku
30 31 32	229	Cancer Center, Nagoya City University Hospital, Toho University Ohashi Medical
33 34 35	230	Center, Osaka International Cancer Institute, and Gifu University Hospital (Figure 1).
35 36 37	231	Table 1 shows the fluoroscopic systems and units performing procedures under
38 39	232	fluoroscopic guidance in each institution. The central sites of the study are located at
40 41 42	233	the Toyonaka Municipal Hospital and Kindai University. The participating physicians
43 44 45	234	are gastroenterologists or endoscopists, including all experts and trainees working at
43 46 47	235	all involved hospitals. The quality of the fluoroscopic devices will be regularly monitored
48 49 50	236	according to the procedures in each institution.
50 51 52	237	
53 54	238	Study population
55 56 57	239	We will include all patients receiving usual clinical care who undergo the following
58 59	240	treatments and diagnostic procedures under fluoroscopic guidance: 1) ERCP; 2)

241	interventional EUS; 3) balloon-assisted enteroscopy; 4) enteral metallic stent
242	placement; and 5) enteral tube placement. There is no age restriction. We will exclude
243	patients who do not want to participate in this study via the opt-out method on each
244	hospital website and patients who the attending physicians judge to be unsuitable for
245	inclusion in this study.
246	
247	Primary outcomes
248	The primary outcomes will be the total FT (min), RDR (mGy/min), dose-area
249	parameters (AK (mGy) and DAP (Gycm ²) and the total number of imaging studies that
250	the patients who meet the individual inclusion and exclusion criteria will undergo (Table
251	2).
252	
253	Secondary outcome
254	The secondary outcome will be the RE-related factors that affect the radiation dose in
255	each procedure. The details are shown in Table 3.
256	each procedure. The details are shown in Table 5.
257	Setting the sample size
258	According to the preliminary questionnaire survey (data not shown), the numbers of
259	examinations per year in the 8 centers that plan to participate in March 2019 are as
260	follows: 4000 ERCP procedures, 125 EUS procedures, 320 small intestine endoscopy
261	procedures, 44 esophageal stent placements, 150 gastroduodenal stent placements,
262	75 colorectal stent placements, 180 transanal ileus tube placements, and 75 ileus tube
	243 244 245 246 247 248 250 251 252 253 254 255 256 255 256 257 258 259 260 261

BMJ Open

2 3		
4 5		
6 7	263	placements. The ICRP 135 recommends using data from 20-30 facilities to set national
8 9 10	264	DRLs, and a survey for a particular examination in a facility should usually involve the
10 11 12	265	collection of data from at least 20 patients ¹¹ .
13 14	266	To set the DRLs and to reduce intraprocedural variability in each hospital, we set the
15 16 17	267	minimum sample size to at least 400 patients for each procedure. We believe that
18 19 20	268	initially enrolling a high number of facilities and patients is desirable; therefore, we did
20 21 22	269	not set an upper limit for the goals.
23 24	270	
25 26 27	271	Data analysis plan
28 29 30	272	After obtaining the data, we will perform normality tests. Continuous variables will be
30 31 32	273	expressed as medians with interquartile ranges or means with standard deviations.
33 34	274	The categorical variables will be expressed as numbers in each category or as
35 36 37	275	frequencies. To explore surrogate markers of RD, simple linear regression analysis will
38 39 40	276	be performed to identify the relationships between procedure time, FT and RD. A
40 41 42	277	multiple linear regression analysis will be performed to identify the factors related to
43 44 45	278	RD. A P value of 0.05 will be considered statistically significant. All statistical analyses
46 47	279	will be performed with JMP software (SAS Institute, Inc., Cary, NC, USA).
48 49 50	280	
50 51 52	281	Patient and public involvement
53 54	282	Clinical factors related to ERCP and interventional EUS have been retrospectively
55 56 57	283	collected at two sites (Toyonaka Municipal Hospital and Kindai University) $^{ m 2022-24}$. We
58 59 60	284	used those published data to develop plans for the design or implementation of the

1		16
2 3		
4 5		
5 6 7	285	study and to determine the research question or the outcome measures. No patients
8 9 10	286	were asked to advise us on the interpretation or writing up of results. There are no
10 11 12	287	plans to disseminate the results of the research to study participants, but we will
13 14	288	consider disseminating the results of the research to the relevant patient community.
15 16 17	289	
18 19	290	Data collection
20 21 22	291	The clinical factors have been modified to comply with local patient flow and
23 24	292	administrative requirements and have been assessed and approved by the study
25 26 27	293	steering committee. We are collecting the password-protected case report forms by e-
28 29	294	mail from each institution; these will be de-identified after all data have been collected,
30 31 32	295	and all data queries have been addressed. A unique study identification number will
33 34	296	identify each participant and the associated clinical data. Data collection will be
35 36 37	297	performed at 3-month intervals to prevent data loss. Data analysis will take place at the
38 39 40	298	central study site (Kindai University). This study does not require data monitoring due
40 41 42	299	to its nature as an observational study without interventions. Data will be retained for
43 44 45	300	either a minimum of 5 years after the end of the study or for 10 years after publication,
46 47 48	301	whichever is later.
49 50	302	
51 52 53	303	Patient recruitment and schedule
54 55 56	304	Patient recruitment will be carried out at the participating hospitals from May 2019 -
56 57 58 59 60	305	December 2020.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

4 5 6 7 8 9 10 11 12 13 14 15 16 17	306 307	2021: Data analysis and writing and submission of the main manuscript for publication.
	308	Ethics and dissemination
	309	This observational study will be conducted in accordance with the principles of the
	310	Declaration of Helsinki, and approval has been obtained from the Institutional Review
18 19 20	311	Board of Toyonaka Municipal Hospital (2019-02-04) and the institutional review board
20 21 22 23 24 25 26 27	312	of each participating facility. The need for informed consent will be waived via the opt-
	313	out method on each hospital website. The results of this study will be presented at
	314	gastroenterology-, endoscopy-, or radiology-related congresses and will be published
28 29 30	315	in a peer-reviewed journal.
30 31 32 33 34 35 36 37 38 39 40	316	
	317	Discussion
	318	Currently, the establishment of DRLs is an international requirement for protection from
	319	medical radiation. For diagnostic radiology, national and regional DRLs are usually set
40 41 42	320	at the 75% percentile of the distribution of a typical sample dose ²⁵ . All physicians or
43 44 45	321	medical staff who are involved in radiological imaging or procedures under fluoroscopic
43 46 47 48 49 50 51 52	322	guidance should be familiar with the DRL process as a tool for optimizing protection. In
	323	addition, separate DRLs must be established for each country and/or region because
	324	the equipment and procedure protocols can vary among different regions ²⁵ . However,
53 54 55	325	the amount of RE depends on the procedure complexity, patient anatomy, lesion
55 56 57 58 59 60	326	characteristics, disease severity ¹¹ and type of fluoroscopic devices ²⁰ ; thus, setting the
	327	upper limit of radiation use by applying uniform standards is difficult. Generally, DRLs

3 4		
5 6 7	328	are not dose limits and do not help distinguish between good and poor medical
8 9	329	practices ²⁵ . Therefore, a high demand exists for a large amount of real-world evidence.
10 11 12	330	The 2015 Japan DRLs state that the methods for establishing DRLs not only include
13 14	331	setting radiation dose levels but also includes determining the dose quantities and units
15 16 17	332	used to set the DRLs, thus standardizing the methodology for dose measurements,
18 19	333	data collection and identification of the applications of DRLs ¹² .
20 21 22	334	Unfortunately, most gastroenterologists are unfamiliar with not only DRLs but also
23 24 25	335	radiation protection because information on RE from gastrointestinal medical treatment
26 27	336	is currently very scarce, and few RE standards, including DRLs, have been established
28 29 30	337	worldwide. Given this background, the REX-GI study is planned as an observational,
31 32	338	nationwide study in Japan. Our results will help to promote radiation optimization and
33 34 35	339	patient radiation protection in gastroenterology studies, such as digestive endoscopy,
36 37	340	and hepatobiliary and pancreatic procedures.
38 39 40	341	
41 42	342	
43 44 45	343	Author contributions
46 47	344	Nishida T, Hayashi S (Toyonaka Municipal Hospital), and Takenaka M (Kindai
48 49 50	345	University) designed this study. Hosono M (Kindai University) critically reviewed the
51 52 53	346	protocol. Nishida T, Hayashi S (Toyonaka Municipal Hospital), Takenaka M (Kindai
53 54 55	347	University), Kogure H (The University of Tokyo), Hasatani K (Fukui Prefectural
56 57 58	348	Hospital), Yamaguchi S (Kansai Rosai Hospital), Maruyama H (Osaka City University),
59 60		

Page 21 of 42

1 2 3 BMJ Open

3		
5 6 7	349	Doyama H (Ishikawa Prefectural Central Hospita), Ihara H, (Tonan Hospital) Yoshio T
8 9	350	(Cancer Institute Hospital, Japanese Foundation for Cancer Research), Nagaike K
10 11 12	351	(Suita Municipal Hospital), Yamada T (Osaka-Rosai Hospital), Yakushijin T (Osaka
13 14	352	General Medical Center), Takagi T (Fukushima Medical University School of Medicine),
15 16 17	353	Tsumura H (Hyogo Cancer Center), Kurita A (Kitano Hospital), Asai S (Tane General
18 19	354	Hospital), Ito Y (Japanese Red Cross Medical Center), Kuwai T (National Hospital
20 21 22	355	Organization, Kure Medical Center and Chugoku Cancer Center), Hori Y (Nagoya City
23 24 25	356	University Graduate School of Medical Sciences), Maetani I (Toho University Ohashi
23 26 27	357	Medical Center), Ikezawa K (Osaka International Cancer Institute), Iwashita T (Gifu
28 29 30	358	University Hospital), Matsumoto K, and Inada M (Toyonaka Municipal Hospital)
31 32	359	participated this study and will recruit the patients. All authors accepted the final
33 34 35 36	360	version of the protocol (ver. 1.1: 2019-Mar-14, ver.1.5: 2019-July-15).
37 38	361	
39 40 41	362	Acknowledgements and collaborators
42 43	363	We thank all the collaborators who are cooperating in this first nationwide study of the
44 45 46	364	Radiation Exposure from Gastrointestinal Fluoroscopic Procedures in Japan (REX-GI).
47 48	365	The collaborators involved in the REX-GI study are as follows: Mitsuhiro Fujishiro
49 50 51	366	(Nagoya University Graduate School of Medicine), Masashi Yamamoto, Dai
52 53	367	Nakamatsu, Kaori Mukai, Kei Takahashi, Aya Sugimoto, Naoto Osugi, Yu Higaki, Ryo
54 55 56	368	Tomita, Tatsuya Sakamoto, Emi Meren, Kazuki Aochi, Shinji Kuriki, Li-sa Chang, and
57 58 59 60	369	Koji Fukui (Toyonaka Municipal Hospital), Yousuke Nakai (The University of Tokyo),

3 4		
5 6 7	370	Takahiro Suda (Kansai Rosai Hospital), Kazuhiro Matsunaga (Ishikawa Prefectural
8 9	371	Central Hospital), Tetsuya Sumiyoshi (Tonan Hospital), Takashi Sasaki, Atsuko
10 11 12	372	Tamashiro, Hiroyuki Hatamori (Cancer Institute Hospital, Japanese Foundation for
13 14	373	Cancer Research), Takumi Kanagawa, Yuichi Yoshida, Masafumi Naito (Suita
15 16 17	374	Municipal Hospital), Shuji Ishii (Osaka General Medical Center), Takuto Hikichi
18 19 20	375	(Fukushima Medical University School of Medicine), Naoki Fujimoto (Tane General
21 22	376	Hospital), Ikuya Miki (Hyogo Cancer Center), Yuzuru Tamaru (National Hospital
23 24 25	377	Organization Kure Medical Center and Chugoku Cancer Center), Hiromi Kataoka,
26 27	378	Kazuki Hayashi (Nagoya City University Graduate School of Medical Sciences), and
28 29 30	379	Hiroaki Shigoka (Toho University Ohashi Medical Center).
31 32	380	
33 34 35	381	Funding statement
36 37	382	This research received clinical research grants from the Japanese Society of
38 39 40	383	Gastroenterology.
41 42 43	384	
44 45 46 47	385	Publication and data sharing
47 48 49	386	After completion of the study, a main manuscript will be prepared to present the results
50 51 52	387	and will be submitted to a clinical journal for peer review. This study will ensure that the
52 53 54	388	public has access to the published data. A file containing the clean dataset used for the
55 56 57	389	final analysis to determine the main data of the study and an explanation of the
57 58 59 60	390	variables will be made publicly accessible in an anonymized format.

1		21
2		
3 4		
5		
6	391	
7	001	
8	202	Concept for publication
9	392	Consent for publication
10 11		
12	393	The principal investigators will form a publication committee, which will include key
13		
14	394	members of this study, and the committee will grant authorship according to individual
15		
16 17	395	input. Investigators who do not qualify for authorship will be acknowledged by name in
18		
19	396	the final manuscript.
20		
21		
22 23	397	
23 24		
25		
26	000	
27	398	Conflicts of interest statement
28 29		
30		
31	399	None of the authors have any competing interests related to this research.
32		
33	400	
34 35		
36		
37		
38		
39 40		
40		
42		
43		
44		
45 46		
40		
48		
49		
50		
51 52		
52 53		
55		
55		
56		
57		
58 59		
59 60		

Table 1. Fluoroscopic system and units performing procedures under fluoroscopic guidance

Table 1. Fluoroscopic system and	d units performing p	BMJ Open	uoroscopic guidar	omjopen-2019-033604 on 26		22
	Number of Hospital Beds		Fluoroscop			Fluoroscopy Unit
		Company	Device model	Apparatus type	Year of introduction	Location
Toyonaka Municipal Hospital	613	Hitachi	Exavista	Over-tube	2016	Endoscopy
Kindai University	929	Hitachi	Curevista	<u>ू</u> Over-tubर्ङ्च	2017	Endoscopy
The University of Tokyo	1216	Hitachi	Curevista	∃ Over-tub e	2009	Radiology
		Canon Toshiba	Exavista	Over-tube	2013	
		Canon Toshiba	Ultimax-I	Under-tube	2016	
Fukui Prefectural Hospital	880	Hitachi	Versiflex	Over-tube	2008	Endoscopy
Kansai Rosai Hospital	642	Canon Toshiba	Zexira	Over-tube	2011	Radiology
		Canon Toshiba	Ultimax-I	Under-tube	2017	
Osaka City University	891	Hitachi	Curevista	Over-tube	2011	Endoscopy
		Hitachi	Versiflex Vista	Under-tube	2015	Endoscopy
Ishikawa Prefectural Central Hospital	639	Canon Toshiba	Drex-zx80	Over-tubey	2016	Endoscopy
Tonan Hospital	283	Hitachi	Curevista	میں Over-tube	2013	Radiology
		Canon Toshiba	ZEXIRA	ਹੁੱ Over-tube	2016	
		1	1	ted by copyright		1

Page 25 of 42

^
~

				omjopen-2019-03360		23
Japanese Foundation for Cancer Research	686	Canon Toshiba	Ultimax-i	Under-tube	2016	Radiology
Suita Municipal Hospital	431	Hitachi	Versiflex	Under-tub∰	2018	Endoscop
Osaka Rosai Hospital	678	Hitachi	Exavista	Under-tube	2018	Radiolog
Osaka General Medical Center	768	Hitachi	Curevista,	Over-tube	2018	Endoscop
		Hitachi	Versiflex	lownl		
Fukushima Medical University	778	Canon Toshiba	Zexira	Over-tub	2012	Radiolog
School of Medicine		Canon Toshiba	FPD1717	d fron		
Hyogo Cancer Center	400	Hitachi	Curevista	Over-tube	2019	Endoscop
Kitano Hospital	699	Hitachi	Versiflex	Under-tub	2017	Endoscop
		Hitachi	Curevista	Over-tub		
Tane General Hospital	304	Hitachi	Exavista	Over-tub	2011	Radiolog
Japanese Red Cross Medical Center	708	Hitachi	Curevista	Over-tubළි දු	2016	Radiolog
Kure Medical Center and Chugoku Cancer Center	700	Hitachi	Exavista	Over-tube	2010	Endoscop
Nagoya City University Hospital	800	Canon Toshiba	Ultimax-I	Under-tub∯ ፼	2018	Endoscop
Toho University Ohashi Medical	319	Canon Toshiba	Ultimax-I	Under-tube	2018	Radiolog
Center				rotected by copyright		

		BMJ Open		omjopen		
				omjopen-2019-033604		24
Osaka International Cancer Institute	500	Canon Toshiba	Ultimax-I	Under-tub	2017	Endoscopy
Gifu University Hospital	606	Shimadzu	C-Vision Safire	Under-tube	2004	Radiology
				4 by guest. Protected by copyright.		
F	or peer review only -	http://bmjopen.bmj.c	:om/site/about/guide	lines.xhtml		

Table 2. Primary outcomes

Table 2. Primary outcomes	BMJ Open 25 033604 on 26
Factors	Variables B
Patients*	Procedure type
	 Procedure type Age
	• Sex 😼
Fluoroscopic system	 Fluoroscopic device (company, device model, manufacturing y arrived arriv
	 Basic use setting: frame per second (FPS), radiation field (cm²/₂ +
Radiation exposure	Total fluoroscopy time (FT) (min)
	Air-Kerma (AK) (mGy)
	Dose-area product (DAP) (Gycm ²)
	 Total fluoroscopy time (FT) (min) Air-Kerma (AK) (mGy) Dose-area product (DAP) (Gycm²) Total number of roentgenography procedures Radiation dose rate (RDR) (mGy/min)
	 Radiation dose rate (RDR) (mGy/min)

Radiation dose rate (RDR) (mGy/min)
 We will not collect patient weight or height because we will have selected patients of standard size for the Japanese population,
whose weight will range from 50 to 70 kg.
 When the setting changes during the procedure, we will record the basic setting.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Table 3. Secondary outcomes

	BMJ Open 2019-033604 on 20
	en-20
Table 3. Secondar	y outcomes Radiation exposure-related factors
Procedures	Radiation exposure-related factors
ERCP	(A) Surgically altered gastrointestinal anatomy
	Billroth I reconstruction, Billroth II reconstruction, Roux-en-Y recons
	pancreaticoduodenectomy
	(B) Type of endoscope
	(C) Naïve papilla
	(D) Indications for ERCP (including suspicion) are classified into the following five categories:
	1) Choledocholithiasis (maximum diameter, number of stones, presence of cholangitis, tube exchange
	for the above diseases, treatment for choledocholithiasis with or without galloon catheter, basket
	catheter, crusher, etc.)
	2) Distant malignant bile duct stricture (papillary tumor, distal cholangiocarcinoma, pancreatic cancer,
	etc.)
	3) Proximal malignant bile duct stricture (Hilar cholangiocarcinoma, intraRepatic cholangiocarcinoma, gallbladder cancer, etc.)
	ع 4) Pancreatic duct examination (pancreas cancer, intraductal papillary mecinous neoplasm, etc.)
	5) Other diseases apart from those listed above (benign bile duct stricture, pancreatobiliary junction
	abnormality, etc.)
	abnormality, etc.) 000000000000000000000000000000000000
1	
	by copyright
	E E E E E E E E E E E E E E E E E E E

0	7
	1

	BMJ Open 9-2019-03360
	n-2019
	4
	1) Cannulation time
	2) Treatment time
	(F) Experience of the high-volume endoscopist (HVE) or low-volume endoscepist: (LVE) †
	(G) Facility scale: The number of ERCP procedures per year
	(H) Whether the fluoroscopic operator is inside or outside in the fluoroscopy of
	(I) Various treatments (endoscopic sphincterotomy, stone treatment, bile duc pancreatic stent, cytology,
	biopsy, naïve papilla, cannulation method, contrast agent, intubation time, firet-use catheter, large balloon,
	crusher, drainage area or method, stent type used, cholangioscopy)
	(J) Sedation: Medication and the depth of the anesthesia ‡
Interventional EUS	(A) Indication for interventional EUS (EUS-guided hepaticogastrostomy (HGS)), choledochoduodenostomy
	(CDS), cyst drainage (CD), antegrade treatment (AG), rendezvous technique (RV), pancreatic duct drainage
	(PD)
	(B) Total procedure time‡
	1) Endoscope insertion time
	1) Endoscope insertion time 9 2) Treatment time 9
	(C) Facility scale: The number of EUS interventions per year, the number of \vec{E} US-guided fine-needle
	aspiration (FNA) procedures per year
	(D) Double stenting (presence or absence of duodenal stenosis)
	(E) Device
	(F) Scope position
	(F) Scope position (G) Sedation: Medication and the depth of anesthesia
	- by of

2	8
_	_

	BMJ Open	
	n-201	2
	BMJ Open BMJ Open 2019-033604	2
Balloon-assisted	(A) Disease indicating balloon-assisted enteroscopy	
enteroscopy	1) Hemostatic or bleeding confirmation	
	2) Crohn's disease	
	3) Small intestine tumor examination	
	4) Others	
	(B) Insertion site: perioral or transanal	
	(C) Insertion length (cm)	
	1) Hemostatic or bleeding confirmation 2) Crohn's disease 3) Small intestine tumor examination 4) Others (B) Insertion site: perioral or transanal (C) Insertion length (cm) (D) Total procedure time (min) (A) Stent location 1) Esophagus (Upper/Mid-Low/Trans) 2) Gastro-duodenum (Above pylorus/Trans pylorus /Below pylorus) 3) Colon stent (Right/Left/Rectum) (B) Total procedure time (min) § 1) Endoscope insertion time 2) Treatment time	
Enteral metallic stent	(A) Stent location	
placement	1) Esophagus (Upper/Mid-Low/Trans)	
	2) Gastro-duodenum (Above pylorus/Trans pylorus /Below pylorus)	
	3) Colon stent (Right/Left/Rectum)	
	(B) Total procedure time (min) §	
	1) Endoscope insertion time	
	2) Treatment time	
Enteral ileus tube	(A) Disease indicating ileus tube	
placement	(B) Intranasal ileus tube insertion for ileal obstruction or transanal ileus tube metrion for malignant colonic	2
	obstruction 약	
	1) Tube insertion length for peroral ileus tube placement (cm)	
	2) The occlusion site for the transanal tube (Right/Left/Rectum)	
	(D) Total procedure time (min) §	
	2) The occlusion site for the transanal tube (Right/Left/Rectum) (D) Total procedure time (min) §	
	oyrig I	

 Protected by copyright

ERCP: endoscopic retrograde cholangiopancreatography

* Cannulation time is defined as the time from endoscope insertion until successful biliary cannulation, and treatment time is defined as the time from successful biliary cannulation until the scope is removed from the patient. The total procedure time is defined as the time from endoscope insertion until the scope is removed from the patient (cannulation time +treatment time).

 \ddagger Depth of anesthesia is divided into 3 levels based on the Richmond Agitation-Sedation Scale (RASS), Ramsay Scale, and Sedation-Agitation Scale (SAS): good, poor, and very bad. The good level is defined as RASS score: $-5 \sim -1$, SAS score: $1 \sim 3$, and Ramsay score: $3 \sim 6$ equivalent, without additional unplanned doses. The poor level is defined as RASS score: $2 \sim -1$, SAS score: $4 \sim 5$, and Ramsay score: $1 \sim 2$, without physical restraint but with unplanned doses. The very bad level is defined as requiring physical restraint with a force considered dangerous, RASS score: +2 to +4, and SAS score: 6 to 7 regardless of Ramsay score.

+ HVE: Endoscopists with more than 200 ERCP results and who have been involved in ERCP for over 10 years. LVE: Non-HVE endoscopists who perform ERCP.

‡ Endoscope insertion time is defined as the time from endoscope insertion until the initial EUS-guided needle puncture, and treatment time is defined as the time from initial EUS-guided needle puncture until the scope is removed from the patient. The total procedure time is defined as the time from endoscope insertion until the scope is removed from the patient (endoscope insertion time +treatment time).

‡Endoscope insertion time is defined as the time from endoscope insertion until initial guidewire exploration, and treatment time is defined as the time from initial guidewire exploration until the scope is removed from the patient. The total procedure time is defined as the time from endoscope insertion until the scope is removed from the patient (endoscope insertion time +treatment time).

Figure legends

Figure 1. The participating hospitals in this study.

.uspitals in this

References

- Henry MF, Maender JL, Shen Y, et al. Fluoroscopy-induced chronic radiation dermatitis: a report of three cases. *Dermatol Online J* 2009;15(1):3. [published Online First: 2009/03/14]
- 2. NCRP Commentary No. 27: Implications of Recent Epidemiologic Studies for the Linear-Nonthreshold Model and Radiation Protection 2018 [Available from: https://ncrponline.org/wp-

content/themes/ncrp/Pub_announcements/Commentary_No27_overview.pdf accessed July 9th, 2019.

 Park TH, Eichling JO, Schechtman KB, et al. Risk of radiation induced skin injuries from arrhythmia ablation procedures. *Pacing Clin Electrophysiol* 1996;19(9):1363-9. doi: 10.1111/j.1540-8159.1996.tb04216.x [published Online First: 1996/09/01]

- 4. de González AB, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. *The Lancet* 2004;363(9406):345-51. doi: 10.1016/s0140-6736(04)15433-0
- 5. Jaffe D, Bowden GT. Ionizing radiation as an initiator: effects of proliferation and promotion time on tumor incidence in mice. *Cancer Res* 1987;47(24 Pt 1):6692-6.
- Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ* 2013;346:f2360. doi: 10.1136/bmj.f2360

- 7. Khoramian D, Sistani S, Hejazi P. Establishment of diagnostic reference levels arising from common CT examinations in Semnan County, Iran. *Polish Journal of Medical Physics and Engineering* 2019;25(1):51-55. doi: 10.2478/pjmpe-2019-
- Radiological protection and safety in medicine. A report of the International Commission on Radiological Protection. *Ann ICRP* 1996;26(2):1-47. [published Online First: 1996/01/01]
- The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37(2-4):1-332. doi: 10.1016/j.icrp.2007.10.003 [published Online First: 2007/12/18]
- ICRP Publication 105. Radiation protection in medicine. Ann ICRP 2007;37(6):1-63.
 doi: 10.1016/j.icrp.2008.08.001 [published Online First: 2008/09/03]
- Vano E, Miller DL, Martin CJ, et al. ICRP Publication 135: Diagnostic Reference Levels in Medical Imaging. Ann ICRP 2017;46(1):1-144. doi: 10.1177/0146645317717209 [published Online First: 2017/10/27]
- 12. Dignostic Reference Levels Based on Latest Surveys in Japan -Japan DRLs 2015-
 - 2015 [Available from: <u>http://www.radher.jp/J-</u> RIME/report/DRLhoukokusyoEng.pdf accessed July 9th, 2019.
- Hart D, Wall BF. UK population dose from medical X-ray examinations. *Eur J Radiol* 2004;50(3):285-91. doi: 10.1016/S0720-048X(03)00178-5 [published Online First: 2004/05/18]
- 14. Dumonceau JM, Garcia-Fernandez FJ, Verdun FR, et al. Radiation protection in

BMJ Open

digestive endoscopy: European Society of Digestive Endoscopy (ESGE)
guideline. <i>Endoscopy</i> 2012;44(4):408-21. doi: 10.1055/s-0031-1291791
[published Online First: 2012/03/23]
15. Hayashi S, Takenaka M, Hosono M, et al. Radiation exposure during image-guided
endoscopic procedures: The next quality indicator for endoscopic retrograde
cholangiopancreatography. World J Clin Cases 2018;6(16):1087-93. doi:
10.12998/wjcc.v6.i16.1087 [published Online First: 2019/01/08]
16. Adler DG, Lieb JG, 2nd, Cohen J, et al. Quality indicators for ERCP. Gastrointestinal
endoscopy 2015;81(1):54-66. doi: 10.1016/j.gie.2014.07.056 [published Online
First: 2014/12/07]
17. Matsuda K, Tanaka K, Fujishiro M, et al. Design paper: Japan Endoscopy Database
(JED): A prospective, large database project related to gastroenterological
endoscopy in Japan. Digestive endoscopy : official journal of the Japan
Gastroenterological Endoscopy Society 2018;30(1):5-19. doi:
10.1111/den.12964 [published Online First: 2017/09/15]
18. Diagnostic reference levels in medical imaging: review and additional advice. Ann
ICRP 2001;31(4):33-52. [published Online First: 2003/04/11]
19. Lynskey GE, 3rd, Powell DK, Dixon RG, et al. Radiation protection in interventional
radiology: survey results of attitudes and use. Journal of vascular and
interventional radiology : JVIR 2013;24(10):1547-51 e3. doi:
10.1016/j.jvir.2013.05.039 [published Online First: 2013/07/24]

20. Hayashi S, Nishida T, Matsubara T, et al. Radiation exposure dose and influencing

factors during endoscopic retrograde cholangiopancreatography. *PloS one* 2018;13(11):e0207539. doi: 10.1371/journal.pone.0207539 [published Online First: 2018/11/20]

- Strahlenschutz Bf. Bekanntmachung der aktualisierten diagnostischen Referenzwerte f
 ür diagnostische und interventionelle R
 öntgenanwendungen Vom 22. Juni 2016
- 2016 [Available from: <u>https://www.klinikum.uni-</u> heidelberg.de/fileadmin/strahlenschutz/linkimages/PDF/DRW-XRay-2016-07-<u>15.pdf</u> accessed Nov 9 2019.
- 22. Hayashi S, Nishida T, Shimakoshi H, et al. Mo2020 Novel Processing Engine for X-Ray Fluoroscopic Images (Faice-V Ns1) Can Reduce Radiation Exposure in the Procedure of ERCP But Keep the Quality of Images. *Gastrointestinal endoscopy* 2017;85(5):AB518. doi: 10.1016/j.gie.2017.03.1207
- 23. Hayashi S, Higaki Y, Tomita R, et al. 940 Disease Site and Processing Engine Affect Radiation Exposure Dose during Ercp. *Gastrointestinal endoscopy* 2018;87(6):AB137. doi: 10.1016/j.gie.2018.04.1348
- 24. Takenaka M, Hayashi S, Nishida T, et al. Mo1090 EXAMINATION OF ACTUAL RADIATION EXPOSURE DOSE OF THE PATIENTS WHO PERFORMED EUS-GUIDED DRAINAGE (EUS-BD/EUS-PD/EUS-CD). Gastrointestinal endoscopy 2019;89(6):AB444-AB45. doi: 10.1016/j.gie.2019.03.1247
- 25. Vassileva J, Rehani M. Diagnostic reference levels. *AJR Am J Roentgenol* 2015;204(1):W1-3. doi: 10.2214/AJR.14.12794 [published Online First:

Page 37 of 42

35

1 2 3 4 5	
5 6 7	2014/12/30]
7 8 9	
10 11	
12 13 14	
15 16	
17 18 19	
20 21 22	
23 24	
25 26 27	
28 29	
30 31 32	
33 34 35	
36 37	
38 39 40	
41 42	
43 44 45	
46 47	
48 49 50	
51 52 53	
54 55	
56 57	
58 59	

BMJ Open: first published as 10.1136/bmjopen-2019-033604 on 26 February 2020. Downloaded from http://bmjopen.bmj.com/ on April 17, 2024 by guest. Protected by copyright.

BMJ Open




Figure 1. The participating hospitals in this study.

119x90mm (300 x 300 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-207

30				
31				Page
32 33 34 35 36 37 38 39 40			Reporting Item	Number
	Administrative			
	information			
	Title	<u>#1</u>	Descriptive title identifying the study design, population,	1
40 41 42			interventions, and, if applicable, trial acronym	
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Trial registration	<u>#2a</u>	Trial identifier and registry name. If not yet registered, name of intended registry	6, 11
	Trial registration: data set	<u>#2b</u>	All items from the World Health Organization Trial Registration Data Set	6, 11
	Protocol version	<u>#3</u>	Date and version identifier	16
	Funding	<u>#4</u>	Sources and types of financial, material, and other support	17
	Roles and	<u>#5a</u>	Names, affiliations, and roles of protocol contributors	15
	responsibilities: contributorship			
	Fo	or peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5 6	Roles and responsibilities: sponsor contact information	<u>#5b</u>	Name and contact information for the trial sponsor	N.A.
7 8 9 10 11 12 13 14 15	Roles and responsibilities: sponsor and funder	<u>#5c</u>	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N.A.
16 17 18 19 20 21 22 23	Roles and responsibilities: committees	<u>#5d</u>	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	12, 14
24 25	Introduction			
26 27 28 29 30 31	Background and rationale	<u>#6a</u>	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	8-10
32	Background and	<u>#6b</u>	Explanation for choice of comparators	9
33 34 35 36	rationale: choice of comparators			
37 38	Objectives	<u>#7</u>	Specific objectives or hypotheses	9-10
39 40 41 42 43 44 45	Trial design	<u>#8</u>	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	11
46 47	Methods:			
48 49	Participants,			
50 51 52 53 54 55 56 57	interventions, and outcomes			
	Study setting	<u>#9</u>	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	12
58 59 60		For peer re	view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

1 2 3 4 5	Eligibility criteria	<u>#10</u>	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	12
6 7 8	Interventions: description	<u>#11a</u>	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	N.A.
9 10 11 12 13 14	Interventions: modifications	<u>#11b</u>	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	N.A.
15 16 17 18 19	Interventions: adherance	<u>#11c</u>	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	N.A.
20 21 22 23	Interventions: concomitant care	<u>#11d</u>	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N.A.
24 25 26 27 28 29 30 31 32 33	Outcomes	<u>#12</u>	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	13
34 35 36 37 38	Participant timeline	<u>#13</u>	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	15
39 40 41 42 43	Sample size	<u>#14</u>	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	13
44 45 46 47	Recruitment	<u>#15</u>	Strategies for achieving adequate participant enrolment to reach target sample size	14
48 49 50 51 52 53	Methods: Assignment of interventions (for controlled trials)			
55 55 56 57 58 59 60	Allocation: sequence generation	<u>#16a</u> r peer rev	Method of generating the allocation sequence (eg, computer- generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be <i>v</i> iew only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	N.A.

1 2 3			provided in a separate document that is unavailable to those who enrol participants or assign interventions	
3 4 5 6 7 8 9 10 11 12 13	Allocation concealment mechanism	<u>#16b</u>	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	N.A.
	Allocation: implementation	<u>#16c</u>	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	N.A.
14 15 16 17 18	Blinding (masking)	<u>#17a</u>	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N.A.
19 20 21 22 23 24	Blinding (masking): emergency unblinding	<u>#17b</u>	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N.A.
25	Methods: Data			
26 27	collection,			
28 29	management, and			
30	analysis			
31 32 33 34 35 36 37 38 39 40 41 42	Data collection plan	<u>#18a</u>	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	14
43 44 45 46 47	Data collection plan: retention	<u>#18b</u>	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
48 49 50 51 52 53 54	Data management	<u>#19</u>	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	15
55 56 57 58 59 60	Statistics: outcomes	<u>#20a</u> or peer re	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	14

1 2 3	Statistics: additional analyses	<u>#20b</u>	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N.A.
4 5 6 7 8 9	Statistics: analysis population and missing data	<u>#20c</u>	Definition of analysis population relating to protocol non- adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	15
10 11	Methods: Monitoring			
12 13 14 15 16 17 18 19 20 21	Data monitoring: formal committee	<u>#21a</u>	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	15
22 23 24 25 26	Data monitoring: interim analysis	<u>#21b</u>	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	15
27 28 29 30 31 32	Harms	<u>#22</u>	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	N.A.
33 34 35 36 37	Auditing	<u>#23</u>	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N.A.
38 39	Ethics and			
40 41	dissemination			
42 43 44	Research ethics approval	<u>#24</u>	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	15
45 46 47 48 49 50 51	Protocol amendments	<u>#25</u>	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	N.A.
52 53 54 55 56 57 58 59	Consent or assent	<u>#26a</u>	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) view only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	15
60	FU	peerie	wew only - http://binjopen.binj.com/site/about/guidelines.xittini	

Consent or assent: ancillary studies	<u>#26b</u>	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N.A.	
Confidentiality	<u>#27</u>	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14	
Declaration of interests	<u>#28</u>	Financial and other competing interests for principal investigators for the overall trial and each study site	17, 18	
Data access	<u>#29</u>	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	17	
Ancillary and post trial care	<u>#30</u>	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N.A.	
Dissemination policy: trial results	<u>#31a</u>	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	14	
Dissemination policy: authorship	<u>#31b</u>	Authorship eligibility guidelines and any intended use of professional writers	18	
Dissemination policy: reproducible research	<u>#31c</u>	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N.A.	
Appendices				
Informed consent materials	<u>#32</u>	Model consent form and other related documentation given to participants and authorised surrogates	N.A.	
Biological specimens	<u>#33</u>	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N.A.	
None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution License CC-BY-ND 3.0. This checklist can be completed online using <u>https://www.goodreports.org/</u> , a tool made by the <u>EQUATOR Network</u> in collaboration with <u>Penelope.ai</u>				